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ABSTRACT 
Patients with end stage renal disease (ESRD) often require hemodialysis treatments in 
which blood’s water and dissolved solutes undergo diffusion and convection by exposure 
to an extracorporeal membrane. The leading cause of death in this population is 
cardiovascular, and how hemodialysis is prescribed alters total sodium balance, a critical 
determinant of cardiovascular health. We performed retrospective and prospective 
analysis of data from patients in the Southwestern Ontario Regional Hemodialysis 
Program. An increased Dialysate sodium (Dial-Na+) to Pre-dialysis plasma sodium (Pre-
Na+) concentration difference (DPNa+) leads to adverse clinical outcomes in 
hemodialysis patients. The post- to pre-dialysis plasma sodium difference (PPNa+) 
predicts clinical outcomes equally well as DPNa+ so long as Dial-Na+ is within 3 
mmol/L of Pre-Na+. Calculation of DPNa+ requires determination of the Pre-Na+, 
historically thought to be stable in hemodialysis patients and thus termed “setpoint” (SP). 
However, we determined that SP is modifiable by hemodialysis prescription. Finally, an 
equation to predict interdialytic weight gain was created, confirming Dial-Na+, dialysis 
frequency and duration to be modifiable factors affecting IDWG. Further research is 
required to validate this equation prospectively, and to determine the impact of changes of 
SP on cardiovascular morbidity and mortality.  
 
KEYWORDS 
Hemodialysis, end stage renal disease, end stage kidney disease, interdialytic weight gain, 
cardiovascular mortality, sudden cardiac death, dialysate sodium, sodium setpoint, 
diffusive sodium balance, ultrafiltration, osmotic sodium balance, quotidian hemodialysis, 
nocturnal hemodialysis, home hemodialysis. 
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Chapter 1: General Introduction 
  
!!
2!
1.0 General Introduction 
Prevalence of kidney disease in the United States (U.S.) has increased by over 60 times 
from 1973 to 2011.1,2 Now approximately 15% of the population is affected by kidney 
disease,3-5 translating to over 4 million Canadians6 and 40 million Americans.7 
Prevalence estimates have been difficult without a uniform definition of kidney disease; 
fortunately, this was formalized in 2002 (Table 1.1).8  
Stage Glomerular Filtration Rate* 
Kidney 
Damage** 
Prevalence 
(%) 
1 > 90 mL/min/1.73 m2 + 1.8 
2 60-89 mL/min/1.73 m2 +/- 3.2 
3 30-59 mL/min/1.73 m2 +/- 7.7 
4 15-29 mL/min/1.73 m2 +/- 0.4 
5             
“End Stage” 
<15 mL/min/1.73 m2     OR             
renal replacement therapy *** +/- 2.4 
    Table 1.1: Kidney Disease Outcomes Initiative Definition of Kidney Disease 
* Glomerular Filtration Rate defined by a Serum Creatinine, as per Cockcroft-
Gault,9 Modification of Diet in Renal Disease (MDRD)10 or Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI)11 equations 
** Kidney Damage may include urinary abnormality (eg. Microalbuminuria, 
hematuria) or structural abnormality of the kidney 
*** Renal replacement therapy may include peritoneal dialysis, hemodialysis, or 
renal transplantation 
   
Critical in the formal definition is the recognition that kidney disease exists on a 
continuum, and that patients can progress from one stage to the next. Though 15% of the 
population suffers from kidney disease, 2.4% (Table 1.1) have the most advanced “end 
stage” 5, and many of these patients require renal replacement therapy. There are three 
types of renal replacement therapy, being peritoneal dialysis (PD), hemodialysis (HD), 
and renal transplantation (RTx). Hemodialysis is a process in which a patient’s blood is 
exposed to a man-made dialyzer membrane to remove waste products, to restore the 
proper balance of electrolytes such as potassium and phosphate, and to eliminate extra 
fluid from the body. Most recent estimates suggest there are 23,188 Canadians12 and 
398,861 Americans13 with Stage 5 kidney disease so severe that they require renal 
replacement with hemodialysis treatments.  
!!
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 Patients with all stages of kidney disease are at higher risk of cardiovascular death 
than the general population.14-16 The most common cause of death in patients with end 
stage kidney disease is indeed cardiovascular (Figure 1.1).2  
 
Figure 1.1: Causes of Death in Patients with End Stage Renal Disease 
Cardiovascular disease encompasses a wide spectrum of pathologies, but in end-stage 
kidney disease patients using hemodialysis (ESRD-HD), up to 60% of cardiovascular 
deaths are by sudden cardiac death (SCD).17 It is well established that SCD risk increases 
as renal function worsens;18 Several mechanisms have been proposed, including 
hemodialysis prescription,19-26 anemia and vascular access,27-31 atherosclerosis,19,32 
arteriolosclerosis,33,34 volume and pressure overload.20,35-40  
1.1  Hemodialysis 
Of special importance in hemodialysis patients are the separate effects of volume 
overload and pressure exerted upon the left ventricular output,20,35-40 which ultimately 
lead to left ventricular hypertrophy41-49 and death.50,51 In conventional hemodialysis 
!!
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patents, urine output is either absent or insufficient, so hemodialysis is performed three 
times a week to remove solutes and fluids. The increase in weight from the end of a 
hemodialysis session to the start of the next session is called interdialytic weight gain 
(IDWG) (Figure 1.2).  
 
Figure 1.2: Interdialytic Weight Gain in Patients Undergoing Hemodialysis  
       Tuesdays, Thursdays and Saturdays 
Overwhelming evidence suggests that, when corrected for confounding factors such as 
nutritional status,52,53 increases in IDWG lead to increased morbidity and mortality in 
hemodialysis patients.37,38,53-56 Thus, defining strategies that effectively control 
interdialytic weight gain is of clinical importance, and likely will lead to improved 
survival of hemodialysis patients.  
Total body volume is regulated through sodium balance,57 and thus the major 
determinant of IDWG is a patient’s total sodium balance (Equation 1.1).  
 
Equation 1.1: Total Sodium Balance 
IDWG ~ [Na+] Balance = [Na+] intake (oral or intravenous)  
- Urinary [Na+]  excretion - Other (fecal/sweat) [Na+] excretion  
+ [Na+] balance in hemodialysis 
In hemodialysis patients, urinary [Na+] excretion is either non-existent or negligible, and 
fecal and sweat sodium excretion is negligible. Thus, the [Na+] balance in a hemodialysis 
!!
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patient is determined by [Na+] intake (oral or intravenous) and by [Na+] balance in 
hemodialysis. It is well established that dietary oral sodium restriction decreases IDWG 
and left ventricular mass.58,59 Likewise, administration of intravenous sodium chloride 
solution increases IDWG.60,61 However, the effect of [Na+] balance, during hemodialysis, 
on IDWG, is less well understood. An understanding of the biological and physical 
processes involved in hemodialysis, and their effects on total sodium balance, is therefore 
essential to determine how to reduce IDWG, and ultimately, hemodialysis patient 
morbidity and mortality. 
Hemodialysis is a process in which a patient’s blood is exposed to a man-made 
dialyzer membrane to remove waste products, to restore the proper balance of 
electrolytes such as potassium and phosphate, and to eliminate excess body fluid (Figure 
1.3). Blood leaves the patient (Figure 1.3- blue curved arrow) from an intravenous 
catheter, into a hemodialysis machine, where it enters “pre-membrane” into the top of a 
dialyzer, simultaneous to clean dialysate fluid entering the bottom of the same dialyzer. 
After the waste products and excess water are removed, blood leaves the dialyzer, and is 
pumped back into the patient (Figure 1.3- red curved arrow).A  
As blood flows through the parallel array of small caliber cylindrical tubes in the 
operational core of a dialysis machine (the dialysis “membrane”), the material walls of 
the tubing are the hemodialysis membrane.  The flow in each tube is approximately 
parabolic in velocity profile, the fastest in the center, and slowest at the wall. The friction 
between these fluid layers is known as viscosity, or less formally as “stickiness.” 
Mathematically, the viscosity (η), is defined as the ratio of the fluid shear stress (τ,in Pa), 
divided by the fluid shear rate (δv/δr, in s-1 ) [η = τ /(δv/δr), thus having units of Pa.s].  If 
the viscosity of a fluid is independent of shear rate, then the viscosity is said to be a 
Newtonian fluid.  While blood does have a minor dependence of its viscosity on shear !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
A  There are many components to the standard hemodialysis machine, including heaters, 
deaeration, blood tubing, blood and dialysate pumps, blood leak detector, flow meter, 
conductivity cell and display, pH probes, filters, dialysis membrane, and electrical supply. 
However, it is not the objective of this thesis to discuss each individual component. Instead, only 
those components that have a role in sodium balance in hemodialysis are discussed. Furthermore, 
the dialysis machine and components are kept relatively constant from one instrument to another. 
These instruments are also kept relatively constant whether a patient performs their treatment in a 
hospital, or at home. Therefore, the biophysical forces involved in hemodialysis are similar 
regardless of the location of the treatments. 
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rate at very low shear rates, it is considered to be Newtonian in the larger blood vessels 
and within the dialysis instrumentation.  
The removal of waste products and water relies upon passage of blood inside one 
of thousands of hollow fibers,B with dialysate fluid moving in the opposite direction on 
the opposite side (Figure 1.4). Since sodium removal during hemodialysis is critical to 
the total body sodium balance, which in turn is important in cardiovascular and all-cause 
mortality,  a  detailed   understanding  of  all  the  factors  that  contribute  to  intradialytic  
 
Figure 1.3: Hemodialysis Process 
sodium balance is essential. Sodium balance during hemodialysis occurs by both 
diffusion and convection. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
B In nephrology clinical settings, a hemodialysis hollow “fiber” is one of thousands of cylindrical 
“tubes” encased within a hemodialysis “membrane.” 
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Figure 1.4: Dialyzer Hollow Fibers Through Which Blood Flows. 
1.1.1 Diffusion 
The rate of diffusive sodium removal across dialyzer membranes is determined by Fick’s 
law (Equation 1.2). In turn, Fick’s diffusion coefficient depends on a number of factors 
(Equation 1.3). Combining equations 1.2 and 1.3 to determine the rate of diffusive 
sodium removal leads to equation 1.4. 
 
Equation 1.2: Fick’s Law 
δn/δt = -D(A) δc/δd 
 
Equation 1.3: Fick’s Diffusion Coefficient 
D = (κΤ/6πη)(4πΝ/3Μu)1/3 
 
Equation 1.4: Combination of Equations 2 and 3 
δn/δt = (-A) (δc/δd)(κΤ/6πη)(4πΝ/3Μu)1/3 
where δn/δ t = the rate of movement of sodium molecules per unit time (mol/s); D = 
Fick’s diffusion coefficient (m2/s); A = membrane surface area (m2); δc = concentration 
difference (mol/m3) and δd = the distance a sodium molecule must move (m). κ = 
Boltzman’s constant (J/K); T = absolute temperature (Kelvin); η = viscosity [Pa s]; N = 
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Avogadro’s number  (mol-1); M = molecular weight (g/mol); u = partial molar volume 
(m3/mol). 
Boltzmann’s constant (κ = 1.3806 x 10-23 m2kg/s2 deg.K.) and Avogadro’s 
number (N = 6.0221 x 1023 mol-1) are known. Furthermore, dialyzed blood must be 
returned to the patient at a tolerable temperature, between 35.5 and 38.0 degrees Celsius. 
This prevents patient discomfort and hypothermia at low temperatures,62,63 and 
intradialytic hypotension at high temperatures.64-67 Thus, there is only a narrow range for 
the temperature (T), which will be simplified to 36.5 oC, or 309.65 oK. Simplifying for δn 
yields Equation 1.5. 
 
Equation 1.5: Rate of Molecular Movement During Hemodialysis 
δn = (3.09 x10-14) (A) (1/Mu)1/3  (δc)  
 δt   η       (δd) 
where δn = movement of molecules (mol); δt = time (s); A = the area of the dialyzer 
membrane through which molecules move (m2); δc = concentration difference (mol/m3); 
δd = the distance a sodium molecule must move (m); η = viscosity [Pa s)]; M = 
molecular weight (g/mol); u = partial molar volume (m3/mol) 
Thus, diffusive loss of a substance can be increased on hemodialysis by a larger 
dialyzer surface area (A), a shorter distance for a molecule to travel (δd), a greater 
concentration difference (δc), longer time on hemodialysis (δt), and lower blood viscosity 
(η). While the design of dialysis machines and dialyzer membranes is not the goal of the 
research performed for this thesis, a basic understanding is required to establish the 
rationale of our research design. 
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1.1.1.1 Dialyzer Area  
Dialyzer membrane fiber area is a function of both fiber radius and length (equation 6). 
 
Equation 1.6: Hemodialyzer Fiber Area 
A = 2πrL  
  
Where A = fiber surface area (m2), r = fiber radius (m),  
L = fiber length (m). 
 
1.1.1.2 Dialyzer Fiber Radius  
Laminar flow of a Newtonian fluid at constant velocity can be modeled using Poiseuille’s 
equation (equation 1.7). On the one hand, a small inner diameter is desirable because it 
decreases the diffusive distance for solute mass transfer (equation 1.5). However, the 
flow along the length of a hollow fiber is governed by the Poiseuille equation (equation 
1.7), which can be rearranged for blood flow (equation 1.8). 
 
Equation 1.7: Poiseuille’s Law 
ΔP = 8(η)(Q)(L) 
 πr4 
 
Equation 1.8: Blood Flow as per Poiseuille Equation 
Q = ΔP/R  where  R = 8ηL/πr4 
Where ΔP = pressure difference between two points (P2 and P1) along a tube, η = fluid 
viscosity [Pa s)], Q = volumetric flow rate (m3/s), r = radius of tube (m), R = resistance to 
blood flow, L = fiber length (m) 
R and r4 are inversely related; small decreases in hollow fiber radius (r) cause 
large increases in flow resistance (R). In general, however, the principal resistance to 
molecular movement out of dialysis tubing is the hollow fiber material itself with a minor 
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contribution to the radial distance within the blood itself. Since blood flow rate is 
constant during hemodialysis, an increase in flow resistance is matched with a large 
increase in pressure drop. This pressure drop is problematic; osmotic clearance is 
optimized by maximizing a dialyzer membrane’s water permeability. Therefore, high 
flow resistance and associated large pressure drop associates with backfiltration of 
dialysate into the blood compartment.68 This is undesirable, as backfiltration is associated 
with endotoxin exposure, activation of complement, cytokines, inflammation, 
malnutrition and death.69-73 Modifications in hollow fiber radius are thus limited, 
reflecting a compromise between these opposing forces;74 most hollow fibers have a 
relatively standard inner diameter (180-220 µm). 
 
1.1.1.3 Dialyzer Fiber Length  
Like dialyzer fiber radius, the fiber length represents a compromise between opposing 
forces.74 On the one hand, an increase in diffusive capacity can be achieved by increasing 
the fiber area (equation 1.3), which is dependent upon the fiber length (equation 1.6). On 
the other hand, increased fiber length associates with higher flow resistance (equation 
1.8) and larger pressure drop, which leads to backfiltration of dialysate into the blood 
compartment.68 This is undesirable, as backfiltration leads to endotoxin exposure, 
activation of complement, cytokines, inflammation, malnutrition and death.69-73 The 
spectrum of hollow fiber length is thus narrow, reflecting a compromise between these 
opposing forces;74 most hollow fibers have a standard length (20-24 cm).  
1.1.1.4 Distance for Molecule to Travel 
The distance for a molecule in blood to travel, to enter the dialysate, is determined by the 
hollow fiber radius, and the fiber wall thickness (Figure 1.5). Considerations for hollow 
fiber radius are discussed above (Section 1.1.1.2).  
The hollow fiber thickness reflects three competing manufacturing constraints. 
Firstly, the fiber wall must withstand the shear stresses of high blood flow under pressure. 
Shear stress is the external force that blood acts upon the hollow fiber, parallel to the 
plane in which the fiber lies. This relationship is dictated by the Poiseuille equation 
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(equation 1.9). Shear stress against the hollow fiber wall also exerts itself against red 
blood cells, making them susceptible to hemolysis. However, the risk of hemolysis in 
modern hemodialysis machines is very low; thus, shear stress lies within well tolerated 
physiological limits. Secondly, greater membrane biocompatibility leads to 
improvements in complement activation,75 inflammation,76 nutritional status,77 
cardiovascular outcomes72 and mortality.72,78,79 The earliest hemodialysis membranes, 
made of modified or unmodified cellulose,68 had low biocompatibility. These had a wall 
thickness of 6-15 µm.80 The major constituent of these membranes was cellobiose,81 
which contained a high density of hydroxyl groups that activated the alternative 
complement pathway.82 Newer synthetic membranes have successfully replaced the 
hydroxyl group and improved biocompatibility. 
 
Equation 1.9: Shear Stress on Hollow Fiber Wall 
τ = 4ηv/r or  τ = 4ηQ/πr3 
Where τ = shear stress on hollow fiber wall (Pa), η  = blood viscosity [Pa s)],  
v = average blood velocity within hollow fiber (m/s), r = fiber radius (m),  
Q = blood flow rate (m3/s) 
Thirdly, earlier hemodialysis membranes had a low mean pore size, limiting clearance to 
only lower molecular weight toxins.83,84 On the other hand, a number of synthetic 
membranes have been developed, including polysulfone,85 polyamide,86 
polymethylmethacrylate,87 polyethersulfone,88 and polyethersulfone combined with 
polyamide.89 These membranes have higher water permeability and larger pore size, 
permitting improved clearance of higher molecular weight proteins.85,90 Increased 
clearance of higher molecular weight proteins, such as β2-microglobulin, is desirable 
since it has been strongly linked to decreased incidence of neuropathy,70,91,92 
cardiovascular disease93-95 and less strongly to death.94,96 In light of these manufacturing 
limitations and clinical outcomes, newer hemodialysis membrane fibers tend to be 
thicker-walled (> 20 µm).74  
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1.1.1.5 Concentration Difference 
The hemodialysis membrane concentration difference is determined by the concentration 
of substance inside hollow fibers (blood) and outside the fiber (dialysate) (Figure 1.5).C 
However, hemodialysis is needed thrice weekly to achieve a minimal weekly 
hemodialysis clearance to achieve benefits in patient morbidity and mortality.93,97-102 
Therefore, patients’ maximal blood substance concentration reflects two things, being the 
duration and the rate of substance production in the interdialytic interval. 
 
Figure 1.5: Schematic of Solute (*) Inside Dialyzer, Crossing Distance of Hollow Fiber  
       Radius and Fiber Wall to Dialysate 
As the interdialytic interval duration increases, substance concentration increases. 
However, changes in dialysis frequency have more pronounced impacts on the 
interdialytic interval duration (Table 1.2). For example, a 50% increase in dialysis 
duration from 4 to 6 hours (hemodialysis prescription 1 to 2) decreases interdialytic 
interval 5.3% (38 to 36 hours), but a similar 50% increase in dialysis frequency from 4 to 
6 times per week (hemodialysis prescription 1 to 3) decreases interdialytic interval 36.8% 
(38 to 24 hours). More frequent hemodialysis schedules have been associated with 
improved blood pressure,103,104 phosphate control,103 physical function,105 left ventricular 
mass,42,103 and cardiac function.106 However, frequent (>4 sessions per week) dialysis 
modalities of short (<4 hours per session) duration may in fact increase patient mortality, 
compared to equal frequency but similar or longer duration.107 This is probably because 
of increased dialysis access related complications108 and increased myocardial stunning 
secondary to higher fluid removal rates.26,64,109-111 Thus, it is likely that both hemodialysis !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
C Nephrologists, and indeed nephrology literature, refers to the concentration difference between 
dialysate and pre-dialysis sodium, or between post- and pre-dialysis sodium as the DPNa+ or 
PPNa+ “gradient.” However, the term “gradient” implies a distance factor, which is not included 
in the nephrology “gradient” description. To avoid confusion, this thesis uses the term 
concentration “difference” whenever possible, except in published nephrology work, which 
interchangeably uses “gradient.”  
! ! ! ! ! ! ! ! ! !
Dialysate Dialysate 
* 
* * * 
* * 
* * * 
* * 
* * * 
* * 
* * * 
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frequency and duration impact diffusive sodium balance, and thus cardiovascular and 
overall patient mortality. The rate of substance production during the interdialytic period 
is determined by body mass, body composition, nutritional status and general health.98 
Indeed, a U shape curve is found for intradialytic urea reduction rate (x-axis) and survival  
(y-axis); lower survival rates at the lower urea reduction rates reflect poor nutritional 
status, anorexia, and muscle wasting, all of which are low toxin generation states.  
 
Hemodialysis 
Prescription 
Frequency 
(sessions per week) 
Duration        
(hours per session) 
Interdialytic 
Interval (hours) 
1" 4 4 38 
2" 4 6 36 
3" 6 4 24 
4" 6 6 22 
Table 1.2: Interdialytic Interval of Four Hemodialysis Prescriptions 
 Maximal concentration difference requires a low concentration in the dialysate 
concentration (Figures 1.3 and 1.5). For most toxins, a low pre-membrane dialysate 
concentration facilitates maximal diffusive removal. However, rapid concentration shifts 
during hemodialysis are associated with patient morbidity and mortality for some 
substrates, requiring standard dialysate concentrations of sodium and chloride,112,113 
calcium,112,114-116 potassium,117 bicarbonate and acetate,118,119 magnesium112 and glucose 
(Table 1.3).120 Maximal concentration difference is supported by the countercurrent flow 
of blood inside and dialysate outside of the hollow fibers (Figures 1.3 and 1.6). Blood 
flow rate of 350-400 mL/min and dialysate flow rates of 500 mL/min are standard, since 
higher flow rates do not significantly increase small molecular weight solute (eg. Urea) 
clearance.121 
1.1.1.6 Concentration Difference - Sodium 
In patients without kidney disease, plasma sodium concentration is stabilized by 
thirst and ADH responsive osmoreceptors located in the hypothalamus122 and the 
organum vasculosum of the lamina terminalis.123,124 Plasma osmolality is calculated by 
concentrations of glucose, urea and sodium (Equation 1.10).  
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Equation 1.10: Calculated Plasma Osmolality 
Osmolality = 2 [Sodium] + [Urea] + [glucose] 
Where Sodium, urea and glucose are in mmol/L, and osmolality is in mOsm/kg. 
 
Dialysate Constituent Concentration (mEq/L) 
Sodium (Na+) 135 to 145 mmol/L 
Chloride (Cl-) 105 mmol/L 
Calcium (Ca++) 2.5 to 3.5 mEq/L 
Acetate 4.0 mEq/L 
Potassium (K+) 1.5 to 3.0 mmol/L 
Bicarbonate (HCO3-) 33 to 38 mmol/L 
Magnesium (Mg++) 0.75 mEq/L 
Glucose 5 to 10 mmol/L 
Table 1.3: Dialysate Composition 
Tight regulation maintains body fluid osmolality between 280 and 295 mOsm/kg water 
by restoring plasma sodium to a patient specific “setpoint” that is stable over time (Figure 
1.7).125,126,127 While the sodium setpoint is well established in people with normal renal 
function,126 it was not until 1991  that  it  was  confirmed  in  patients  with  severe  
kidney disease,128 and until 2007 that is was confirmed in conventional (< 4 hour per 
session) thrice weekly hemodialysis patients.129-131  However, recent evidence  suggests  
that  thehemodialysis procedure can alter intradialytic plasma sodium concentrations.132 
Moreover, previous reports of sodium setpoint stability in hemodialysis patients excluded 
patients with certain comorbid illnesses, had limited plasma sodium measurements, and 
only considered patients whose hemodialysis sessions were 4 hours or less in duration, 
and 3 times a week. Establishing if the sodium setpoint can be modified in frequent or 
longer hemodialysis is essential, since hyponatremia (low plasma sodium) has been 
associated with increases in all-cause mortality.133,134 The results of previous trials that 
show a survival advantage in longer hemodialysis135,136 and increased mortality in more 
frequent hemodialysis107 may relate to changes in the pre-dialysis plasma sodium setpoint 
(hypothesis 2.1).  
!!
15!
 
 
 
Legend:                   Blood flow;          Dialysate flow 
Movement of waste product 
 
Figure 1.6: Waste Product Concentration with Countercurrent (A)  
and Concurrent (B) Flow 
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Diffusive balance of sodium during hemodialysis is determined by the 
concentration difference between the pre-hemodialysis plasma sodium concentration 
(Pre-Na+) inside, and the dialysate sodium concentration (DialNa+) outside the 
hollowfiber. In conventional thrice weekly hemodialysis patients, a positive dialysate to 
plasma sodium difference (Dial-Na++ > Pre-Na+) is associated with increased blood 
pressure, IDWG and cardiovascular morbidity and mortality.137-140 On the other hand, a 
negative dialysate to plasma sodium difference  (Dial-Na++ < Pre-Na+)   is   associated   
with   intradialytic   hypotension,  which  is  an independent predictor of death.132,141 
Given these factors, considerable debate persists regarding the appropriateness of 
personalizing dialysate sodium concentration to minimize adverse outcomes. It is 
uncertain whether the dialysate to pre-dialysis plasma sodium   concentration    
difference, or   the    pre-dialysis   to    post- dialysis   plasma   sodium concentration 
difference is preferable to predict clinical outcomes. Furthermore, the predictive value of 
dialysate, pre- and post-dialysis plasma sodium concentrations has not been evaluated in  
 
 
 
Figure 1.7: Homeostatic Mechanism for Plasma Osmolality  
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a hemodialysis population on longer or more frequent hemodialysis sessions. This has 
special relevance in the design of prospective clinical trials in frequent hemodialysis 
modalities, and in the clinical monitoring of such patients (hypothesis 2.2).  
A hemodialysis patient’s albumin concentration influences the amount of sodium 
available for diffusion. Since the anionic albumin is impermeable across hemodialysis 
membranes, its negative charge leads to an electrochemical gradient, leaving less than 
100% of plasma sodium available for diffusion.142 Since plasma albumin concentration is 
variable, this “Gibbs-Donnan effect” may be relevant to diffusive sodium loss during 
hemodialysis (hypothesis 2.3).  
One of the other two components of calculated osmolality is blood glucose 
(equation 1.10). In diabetes mellitus, a quantitative or qualitative insulin deficiency 
prevents glucose movement into cells, leading to hyperglycemia in the extracellular 
space. As hyperglycemia worsens, extracellular fluid osmolality increases (equation 1.10) 
and exceeds that of the intracellular fluid, leading to movement of water out of cells into 
the extracellular fluid. Plasma sodium concentration falls in proportion to the dilution of 
the extracellular fluid, falling approximately 1.6 mEq/L per 5.5 mmol/L increase in blood 
glucose concentration.143 It is thus plausible that the hyperglycemic milieu of diabetes   
alters water and sodium balance during hemodialysis; this has not been well studied 
(hypothesis 2.3). 
1.1.1.7 Time on Hemodialysis 
The maximal duration for conventional hemodialysis treatment was, until recently, 
dictated by facility resources, and ultimately by cost; personnel costs, laboratory tests, 
building maintenance, electricity, water, and administrative costs limited most patients to 
a maximum of four hours per session,144-147 within one of the three hemodialysis shift 
times (8 AM to 12 PM, 12:30 PM to 4:30 PM, 5 PM to 9 PM). However, when compared 
to conventional hemodialysis, sessions longer than 4 hours associate with improvement 
of multiple ESRD-associated conditions. While improved phosphate balance,104,148-151 
renal anemia,148,152 and fertility153 are well accepted, the pathophysiology of improved 
blood pressure,148,150 left ventricular hypertrophy,42,103,154,155 and mortality135,136,156,157 
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remain controversial. There are also cost reductions with home nocturnal (6 to 8 hours 
per session) hemodialysis ($36,840 to $61,220 per annum), compared to in-center 
conventional (4 hours maximum per session) thrice weekly hemodialysis of four hours 
($58,959 to $100,198 per annum).158-161 However, longer hemodialysis treatments are not 
preferable for all patients, as the quality of life has not consistently shown differences 
between hemodialysis modalities.162 Health care administrators have thus advocated for 
more patients to undergo their hemodialysis treatments at home, while many 
nephrologists have advocated for those home treatments to be of longer duration than 4 
hours. Understanding how to optimize hemodialysis duration, within the confines of cost 
and patient comfort, has the potential to improve patient morbidity and mortality.  
In the London Daily Nocturnal Dialysis study,148 IDWG was higher in frequent 
nocturnal (>4 sessions per week, >6 hours per session) than in short hours daily (> 4 
sessions per week, < 4 hours per session) hemodialysis patients using a standard dialysate 
sodium concentration of 140 mmol/L, suggesting that the time of exposure to a higher 
dialysate sodium may affect IDWG. On the other hand, the Frequent Hemodialysis 
Network (FHN) showed lower IDWG in the frequent nocturnal hemodialysis patients,150 
but the patients in this study had variable dialysate sodium concentrations and higher 
residual urinary volumes. This raised the possibility that the time of exposure to a 
diffusive sodium difference was of importance to IDWG (hypothesis 2.3). Likewise, 
whether residual urinary volume affected IDWG was unknown (hypothesis 2.3). Since 
longer hemodialysis duration translates to longer exposure of blood to a diffusive sodium 
difference (equation 1.1), this will alter IDWG and thus cardiovascular morbidity and 
mortality.37,38,53-56 
1.1.1.8 Viscosity 
As blood viscosity increases, diffusive solute loss from blood into dialysate decreases 
(Equation 1.5). The major determinants of blood viscosity are temperature,163 
hematocrit164,165 and plasma protein concentration.166 Tables of blood viscosity based on 
plasma albumin and blood hematocrit167,168 are accurate at low shear rates, but may not 
apply to hemodialysis patients whose blood flows from and back into an arteriovenous 
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fistula, graft or intravenous catheter during hemodialysis (Figure 1.3). However, even at 
the conditions of hemodialysis, the major predictors of blood viscosity have consistently 
been confirmed to be the same.169-172 Since temperature is determined by patient 
hemodynamic stability and symptoms (35.5 to 38.0 degrees Celsius, see section 1.1.1, 
equation 1.4), the remaining factors of importance are hematocrit and plasma protein 
concentration.  
 Progression of kidney disease leads to an erythropoietin deficiency and 
anemia.173,174 Correction of anemia is associated with increases in hematocrit, blood 
viscosity and reduced diffusive hemodialysis clearance.175 However, it is other clinical 
endpoints that determine current guidelines for target hemoglobin of 11.0 to 12.0 g/dL in 
hemodialysis patients;176,177 considerable evidence shows that normalization of 
hemoglobin >13.0 g/dL associates with increased rates of cerebrovascular disease, 
myocardial infarction and death.178-183  
 Under most physiologic circumstances, plasma protein concentration is 
determined by the most abundant plasma protein albumin. Hypoalbuminemia (<35 g/L) 
is associated with cirrhosis, chronic inflammation or infection, and malnutrition.184-186 
Hyperalbuminemia (>50 g/L) is much less common,187 being described in high protein 
diets.188  
Concerns have arisen in studies showing that blood viscosity does not consistently 
decrease with decreasing vessel diameter. This Fahreus-Lindqvist effect has been 
conclusively confirmed in vitro;169,189-196 when blood flows in tubes of decreasing 
diameter, relative viscosity decreases.197 This effect is exaggerated once tube diameter 
falls below 1.0 mm; the dialyzer hollow fiber diameter of 0.18 to 0.22 µm (section 
1.1.1.2) means a ~20% reduction in relative blood viscosity, due to the Fahreus-Lindqvist 
effect.195,198 
 Poiseuille’s law and each of its derivations (equations 1.7 and 1.8) make a number 
of assumptions. Firstly, blood should be an incompressible Newtonian fluid with constant 
viscosity.199 However, blood is non-Newtonian in at least two ways;195 the pressure-flow 
curve is probably not linear,200,201 and shear stress is dependent on blood viscosity. 
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However, blood viscosity still has the same predictors despite the non-Newtonian 
factors;163,202 while the relationship may not be perfectly linear, equations 1.7 and 1.8 still 
provide a reasonable first estimation to identify clinical factors of importance. Secondly, 
there should not be acceleration of fluid in the pipe. This condition holds true for standard 
hemodialysis, since a set blood flow rate from the patient maintains a constant blood flow 
rate through thousands of standardized hollow dialyzer fibers.74 Thirdly, the hollow fiber 
length must be substantially greater than the diameter to avoid the entrance-length 
effect203,204; a length of greater than 10 times diameter is usually sufficient to overcome 
this issue.205 Since the average hollow fiber radius is 180 to 220 µm (section 1.1.1.2), and 
the hollow fiber length 20 to 24 cm (section 1.1.1.3), the entrance-length effect is 
insignificant in hemodialysis. Fourthly and finally, blood flow through a dialyzer should 
be laminar, which holds true under most circumstances.206,207 This can be confirmed by 
calculation of a Reynolds number for the conditions of blood flowing through a hollow 
fiber in a dialyzer for a standard hemodialysis patient.  
Equation 1.11: Reynolds Number for Blood Flow in Dialyzer Hollow Fiber 
Re  = ρ v dH          
                      η !
Where  Re = Reynolds number,!ρ = density (kg/m3), v = velocity (m/s), dH = diameter, 
η = viscosity (Pa s). 
 
Dialyzer fiber diameter is approximately 400 mm (section 1.1.1.2), the whole blood 
density ranges from 1043 to 1057 kg/m3, and blood viscosity ranges from 3 to 4 x 10-3 
(Pa s) at 37 degrees Celsius.208 Blood flow during hemodialysis is set to 400 mL/min; 
assuming 12,500 hollow fibers per dialyzer and a fiber radius of 200 mm, the blood 
velocity is 0.00424 m/s. Using these values, the Re of blood in a hollow fiber during 
dialysis is  0.5088, well below the upper limit cutoff for laminar flow, which Reynolds 
initially described to be approximately 2100.209,210  
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1.1.2 Convection 
Convection, also known as ultrafiltration, is the movement of water across a semi-
permeable membrane due to hydrostatic or osmotic pressure.211 The dialysis machine 
pump exerts a negative pressure on the dialysate compartment and a positive pressure in 
the blood compartment, leading to water and dissolved substances leaving the blood into 
the dialysate (“solvent drag”) (Figure 1.8).212 When dialysate and patient plasma sodium 
concentrations are equal, no diffusive difference is present. Intradialytic sodium loss is 
then entirely dependent on negative convective balance.211 
 
Figure 1.8: Blood and Dialysate Compartment Pressures Leading to Net    
           Transmembrane Pressure for Convection.  
Convective fluid losses during hemodialysis have pronounced impact on the 
compartments that make up total body water. In an average healthy 70 kg man, 
approximately 60% of body mass (42 kg) is made up of water, of which 2/3 (28 kg) is 
intracellular and 1/3 (14 kg) is extracellular.213 However, if the same man becomes anuric 
and hemodialysis-dependent, interdialytic weight gains lead to expansion of both 
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intracellular and extracellular fluid compartments (Figure 1.9). Fluid expansion forms the 
basis of clinical dry weight assessment by examining for interstitial fluid expansion  
(edema) and intradialytic hypotension (Figure 1.9).213 However, it is well recognized that 
a hemodialysis patient  can  have  fluid excess     without   clinical   evidence  of    
volume expansion,   commonly    called   “silent   overhydration.” 214-216 Furthermore,  
Figure 1.9: Total Body Water in Healthy 70 kg Man (A) and Hemodialysis Patient With  
       Dry Weight of 70 kg but with 6 kg Interdialytic Weight Gain (B) 
relative proportions of compartments of total  body water differ  significantly  depending  
on  sex, race and body habitus (hypothesis 2.3).217 Likewise, intradialytic hypotension 
occurs when increases in plasma volume from compartments outside plasma occur 
slower than hemodialysis reduces plasma volume.64,218 Refilling from the interstitial fluid 
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continues until 4 hours after a hemodialysis session; intradialytic hypotension is therefore 
a poor marker for total body volume status. Expansion of these compartments leads to 
volume overload, pressure overload,20,33,35,37-40 left ventricular hypertrophy,41-49 and 
death.50,51 This   effect  is   even   more   pronounced   when   dry   weight   is    clinically    
assessed  inaccurately  as   in  “silent overhydration”, since hemodialysis will return a 
patient to a persistently volume overloaded state (Figure 1.10).219,220 Given the 
inaccuracies  of  clinical volume assessment, a great deal of research has focused on 
improving evaluation of hemodialysis patient’s total body water status and dry weight. 
However, natriuretic peptides,221-229 diameter of inferior vena cava,222,227,230 and CRIT-
line monitoring231-239 have limited specificity and generalizability ,220,229 and  their  use  
may   even   increase  mortality.236  Perhaps   the  most  promising   is  the  current   “gold  
 
Figure 1.10: Hemodialysis Patients Oscillate from “Wet” to “Dry” State if Clinical  
         Assessment of Dry Weight is Accurate (A). If Dry Weight is Lower Than  
         Clinically Estimated (B), Patient Will Remain “Volume Overloaded” After     
         Hemodialysis 
standard” of multiple-frequency bioimpedance spectroscopy. The resistance of body fluid 
compartments can be measured, with the ratio of the resistances of the intracellular and 
extracellular water reflecting the relative volume of these compartments.240 As 
hemodialysis patients accumulate excess fluid in their extracellular compartment, this 
ratio proves useful in the evaluation of dry weight. Considerable evidence confirms that 
bioimpedance-guided volume assessment of hemodialysis patients is associated with 
improved clinical outcomes,219,241-243 including mortality.219 While evaluation of these 
technologies is not the objective of this document, it should be mentioned that 
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bioimpedance has confirmed that IDWG reduction is insufficient to reduce 
cardiovascular mortality if  “silent overhydration” persists. This is one inherent limitation 
of any clinical work designed to identify strategies to reduce IDWG.  
1.2 Historical Context 
“Optimal” dialysate sodium concentration has changed more frequently and for more 
reasons than likely any other hemodialysis parameter.244 Early prescriptions relied on a 
negative DPNa+ to increase diffusive sodium loss. A Dial-Na+ of 125 to 130 mmol/L 
was standard, and osmotic loss of plasma water was promoted by using high dialysate 
glucose concentrations.244,245 However, treatment times decreased over time, 
necessitating increases in Dial-Na+ to decrease intradialytic symptoms such as 
disequilibrium syndrome.246,247 A Dial-Na+ of 140 mmol/L became standardized for 
patients undergoing hemodialysis thrice weekly. This increase in Dial-Na+ was further 
supported when acetate-based solutions were replaced with bicarbonate-based dialysate,64 
with the observation that higher Dial-Na+ were associated with less intradialytic 
hypotension.53,248,249 With higher Dial-Na+, sodium removal on hemodialysis occurred by 
convection only, with diffusive losses often replaced with diffusive sodium gain. 
Decisions regarding Dial-Na+ became based upon minimizing patient symptoms within 
the confines of having only 4 hours three times a week to assure all sodium and fluid 
removal. This formed the basis of “sodium ramping,” in which higher Dial-Na+ were 
used for all or part of a dialysis session.248-250 Sodium ramping successfully reduced 
symptoms such as cramping, headaches and intradialytic hypotension.248,249 However, 
significant increases in thirst, pre-dialysis blood pressure and interdialytic weight gain 
(IDWG) raised concern that such prescriptions might exacerbate volume overload and 
cardiovascular mortality.244 As such, the use of sodium ramping has largely fallen out of 
favor.  
  As the burden of cardiovascular disease persisted in hemodialysis patients, new 
strategies to counteract the chronic state of volume and pressure overload were sought. 
This led to reevaluation of the standard prescription of thrice weekly hemodialysis of 3 to 
4 hours each session. More frequent and longer hemodialysis are associated with 
improvements in anemia control,152 calcium and phosphate balance,149,251,252 fertility,153 
and volume and pressure overload.42,154,155,253,254 Indeed, nocturnal therapies associate 
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with improved survival by uncertain mechanisms. This thesis examines the impact of the 
present day hemodialysis prescriptions, on diffusive and convective sodium balance. This 
will ultimately establish the effect of sodium balance on cardiovascular morbidity and 
mortality in hemodialysis patients. 
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2.0 Hypotheses 
Hypothesis 2.1: 
Hemodialysis of a duration greater than 4 hours or a frequency greater than 3 times 
weekly has no effect on the pre-dialysis plasma sodium setpoint. This hypothesis was 
evaluated retrospectively in Chapters 3 and prospectively in Chapter 7. 
 
Hypothesis 2.2: 
The dialysate to pre-dialysis plasma sodium difference and the pre- to post-dialysis 
sodium plasma differences will predict clinical outcomes (blood pressure, interdialytic 
weight gain, intradialytic hypotension) equally effectively in a hemodialysis population 
with frequency greater than thrice weekly and session duration greater than 4 hours per 
session. This hypothesis was evaluated retrospectively in Chapter 4 and prospectively in 
Chapter 6.  
 
Hypothesis 2.3: 
IDWG can be predicted by several demographic and clinical factors, which each impact 
sodium balance on hemodialysis. These factors may include patient factors (age, sex, 
body habitus, diabetes status, dietary salt intake), laboratory factors (patient hematocrit, 
plasma albumin and pre-hemodialysis plasma sodium concentration, residual renal 
function), and dialysis factors (dialysate temperature and sodium concentration, dialysis 
time and duration, dialysis membrane hollow fiber length and radius and wall thickness). 
This was evaluated in Chapter 5. 
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Chapter 3: Plasma Sodium Setpoint: Is it Constant or Changed by Hemodialysis 
Prescription? 
 
 
 
 
 
 
 
This chapter has been published as:  
Thomson BK, Huang SH, Chan CT, House AA, Lindsay RM. Plasma sodium setpoint: is 
it constant or changed by hemodialysis prescription? Asaio J. Sep-Oct 2013;59(5):497-
504. 
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3.1 Introduction 
Patients with normal renal function have a specific osmolality value, above which thirst is 
generated and fluid ingested. This “setpoint” results in a relatively stable and 
reproducible plasma sodium level over time, not only in patients without kidney disease,1 
but also in patients with advanced renal disease.2 Evidence of this sodium setpoint is also 
seen in thrice weekly conventional hemodialysis patients.3-5 However, hemodialysis 
patients lack the mechanisms to regulate body osmolality and fluid balance.  While 
previous trials examining the clinical effects of different dialysate sodium concentrations 
have treated pre-dialysis sodium “setpoint” as stable, this assumption has not been 
confirmed in quotidian hemodialysis patients.  
Lower pre-dialysis sodium “setpoint” and higher dialysate sodium concentrations 
lead to important clinical outcomes such as increased blood pressure and IDWG,6-13 
which may effect cardiovascular and all-cause mortality.14,15 Lower pre-dialysis plasma 
sodium is independently associated with increased all-cause mortality,16,17 thus a change 
in sodium “setpoint,” might need ongoing monitoring to minimize IDWG, and associated 
cardiovascular morbidity and mortality. 
The objective of this study was to determine if the sodium setpoint changed with 
longer or more frequent exposure to the same dialysate sodium concentrations, when 
patients transitioned from thrice weekly conventional hemodialysis to dialysis modalities 
differing in duration and frequency.  
3.2  Materials and Methods 
Study Population 
We performed a retrospective observational design that included all patients in the home 
hemodialysis program of the Southwestern Ontario Regional Renal Program, from 1998 
to December 31, 2011. A total of 87 patients, 23 still current and 64 no longer on home 
hemodialysis, were included. All patients in our study were on conventional thrice 
weekly hemodialysis in-center (ICHD) prior to home hemodialysis; some continued 
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ICHD while others changed hemodialysis modality upon transferring from in-center to 
home hemodialysis.  
Dialysis Modality 
The modality of home hemodialysis was defined by the duration of dialysis therapy, and 
the frequency of treatments. Short-hours daily (SHD) hemodialysis was defined as a 
minimum of 5 treatments per week, with a treatment time of 1.5 hours to 4.0 hours. 
Intermittent conventional hemodialysis (ICHD) implied a maximum of 4 treatments per 
week, with treatment times of 1.5 hours to 4 hours.  Frequent nocturnal hemodialysis 
(FNHD) was a minimum of 5 treatments per week, with a minimum treatment time of 6.0 
hours. Intermittent nocturnal hemodialysis (INHD) meant a maximum of 4 treatments per 
week, with a minimum treatment time of 6.0 hours. Dialysate sodium concentration was 
not individualized as it was a standard 140 mmol/L for all patients at all times. 
Blood sample collection 
In the 50 days prior to initiation of home hemodialysis, while the patient is on in-center 
thrice weekly conventional hemodialysis (ICHD-IC), pre and post dialysis blood samples 
are taken every one to two weeks. Upon transition to home hemodialysis, pre and post 
dialysis blood samples are routinely taken each month. Home patients are trained to take 
blood from the arterial blood line at the start of dialysis and post-dialysis, using a 
standard slow blood and stop dialysate method. The samples are centrifuged and then 
stored and refrigerated until delivered to the local laboratory for that patient. All patient 
blood tests are measured using automated and standardized methods. Of interest to this 
study were pre-dialysis plasma sodium concentrations. Only outpatient blood tests were 
used, to assure that the patient was at their baseline health status, so that the plasma 
sodium concentration would not be confounded by acute illness. 
Sodium concentration measurement 
Plasma sodium concentration was measured using Beckman-Coulter LX20 Pro 
Chemistry Analyzer with Ion Selective Electrodes prior to, and Roche Modular P 
Chemistry Analyzer with Ion Selective Electrodes after November 4, 2008. This change 
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was made by the London Health Sciences Center because of a need for higher volume of 
laboratory testing. Both plasma Na+ concentration methods were regularly calibrated; 
thus, the measurements were treated as equivalent on data analysis. Dialysate sodium 
concentration was determined using online conductivity measurements built into the 
Fresenius H series hemodialysis machine, which was used for all patients. Blood glucose 
was not measured simultaneous to Na+ concentration; thus, plasma sodium levels were 
not corrected for glucose. Dialysate Na+ concentration measurement is regularly 
calibrated, to assure stability and accuracy of dialysate Na+ concentrations. Home 
hemodialysis machines were evaluated and calibrated at least once, and usually twice 
annually, by the program’s water engineer or one of the trained home hemodialysis 
nurses. 
Database Creation 
Blood test results were available from the electronic patient record (PowerChart by 
Cerner) of London Health Sciences Centre.  
Age (years), sex, diabetes status, residual renal function (mL/min/1.73m2) and 
months of renal replacement therapy prior to initiation of home hemodialysis were 
determined from chart review. Residual renal function was calculated within 3 months of 
conversion to home hemodialysis, as previously described.18 
Weights (kg), dialysis treatment times and frequency were obtained from archived 
dialysis treatment run sheets. The average values for these per month were calculated and 
entered into the study database. For this analysis, a single value for each patient data 
point was used; the average of the monthly values was used regardless of time period on 
hemodialysis modality. There were no duplicate observations for any patient. 
Ethics 
Because of concerns regarding the use of a standard dialysate of 140 mmol/L sodium 
concentration and prompted by the observation of high IDWGs in patients undergoing 
FNHD, a quality assurance investigation was instituted.  All laboratory tests had been 
taken as per routine care protocols; demographic and dialysis treatment information were 
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available from patient records.  Once extracted, all data were de-identified before 
analysis.  No patient had to provide blood samples, answer questionnaires or do anything 
specific for this study which was conducted in accordance with the Declaration of 
Helsinki.  Thus, informed written consent was not obtained from the current patients.  
Statistics 
Data were analyzed using the Statistical Package for Social Sciences (SPSS, IBM, 
Armonk, New York, U.S.) version 19.0.  
Patients exposed to different dialysis modalities were compared using two-tailed 
student T-tests for continuous variables, and Fisher’s exact test for categorical variables. 
Statistical significance was achieved with α<0.05.  
The objective of this study was to determine if the sodium setpoint changed with 
longer and more frequent exposure to the same dialysate sodium concentrations, when 
patients transitioned from thrice weekly conventional hemodialysis to dialysis modalities 
differing in duration and frequency (SHD, ICHD, INHD, FNHD). The “sodium setpoint” 
was defined as the average pre-dialysis plasma sodium concentration over the time period 
specified for each of three endpoints. The three endpoints were DeltaPRENA100, 
DeltaPRENA100-150, and M100 (Figure 3.1). They are defined as follows: 
DeltaPRENA100 is the difference between PRENA100+ and PRENA-50. 
PRENA100+ is the average pre-dialysis plasma sodium concentration, after 100 days of 
home hemodialysis, for the life of the patient while still on the same dialysis modality. 
PRENA-50 is the average of all pre-dialysis plasma sodium values in the 50 days prior to 
transition to home hemodialysis and while on ICHD.  
Each patient’s period of time on home hemodialysis differed after the first 100 
days. Thus, DeltaPRENA100-150 was also calculated as the difference between 
PRENA100-150 and PRENA-50. The PRENA100-150 is the average pre-dialysis plasma 
sodium concentration, between 100 and 150 days post-transition to home hemodialysis.  
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Figure 3.1: Endpoints to Determine Existence of Sodium Setpoint 
PRENA100+ and PRENA-50 were compared, as were PRENA100-150 and 
PRENA-50 in each dialysis modality group, for all patients, and separately for patients 
with PRENA-50 values a) greater than or equal to, or b) less than the dialysate sodium 
concentration of 140 mmol/L. A statistically significant change between Pre and Post-
Na+ values implied a change in sodium setpoint. 
A line of best fit was then calculated from the pre-dialysis plasma sodium values 
versus time plot for each patient over the first 100 days after transitioning to home 
hemodialysis. The slope of these lines of best fit was measured with its confidence 
intervals (M100). The mean M100 values found in different dialysis modality groups 
were compared overall, and again by PRENA-50/dialysate-Na+ relationship. A M100 
with 95% confidence intervals that did not cross zero was evidence for a change in 
sodium setpoint. 
We chose the time period of 100 days because we wanted a minimum of 3 plasma 
sodium measurements for each patient to calculate slope of pre-dialysis plasma sodium 
concentration. Since each home hemodialysis patient undergoes monthly blood work, 
most patients have a minimum of 3 pre-dialysis sodium concentrations within 100 days.  
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Regression models were used to identify an association between the primary 
outcome DeltaPRENA100 and a series of covariates. Specifically, univariate regression 
analyses were performed using DeltaPRENA100, DeltaPRENA100-150, and M100 as 
separately evaluated dependent variables. Independent variables evaluated included 
dialysis frequency and duration, dialysate to (PRENA-50) difference (DPRENA-50), and 
(DPRENA-50) times dialysis duration. We evaluated (DPRENA-50) times dialysis 
duration, as an independent variable, since we have previously shown that this covariate 
is predictive for interdialytic weight gain in a similar patient population.  
Multivariate regression was used in an attempt to determine how 
DeltaPRENA100 was associated with dialysis frequency, duration, the dialysate to 
PRENA-50 difference, and the dialysate to PRENA-50 difference times dialysis duration. 
Here all patients were used regardless of dialysis modality.  
Table 3.1: Demographic Factors of Dialysis Modality Groups 
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3.3 Results 
A total of 87 patients made up the database, with 31, 13, 30 and 13 from SHD, ICHD, 
FNHD and INHD. There were 29, 13, 28 and 12 patients with sufficient data for 
DeltaPRENA100 and DeltaPRENA100-150, and 31, 10, 26 and 11 patients with 
sufficient data for M100 from SHD, ICHD, FNHD and INHD, respectively. A total of 29 
patients had pre-transition pre-dialysis sodium setpoint greater than or equal to 140 
mmol/L, with 12,3,12, 2 from SHD, ICHD, FNHD and INHD. 
There were no statistically significant differences between dialysis modalities for 
age, diabetes status, sex, or vintage of renal replacement prior to initiation of home 
hemodialysis (Table 3.1). However, FNHD patients were heavier than ICHD patients 
(87.5 versus 68.5 kg, p = 0.008). Residual renal function was higher in ICHD patients 
than SHD patients (1.94 versus 0.27 mL/min/1.73 m2, p < 0.001). While on the assigned 
dialysis modality, plasma albumin did not differ between groups. Pre-dialysis phosphate 
concentration was lower in FNHD than SHD patients (1.56 versus 1.76 mmol/L, p = 
0.044). Dialysis duration was shorter in SHD patients (142.3 min) than ICHD (202.3 min, 
p <0.001), FNHD (408.6 min, p<0.001) and INHD patients (372.5 min, p<0.001), and 
shorter in ICHD patients than FNHD (p<0.001) and INHD patients (p<0.001). Dialysis 
frequency was greater in SHD patients (5.7 per week) than ICHD (3.1 per week, 
p<0.001), FNHD (5.2 per week, p<0.001) and INHD patients (3.1 per week, p<0.001), 
and greater in FNHD than ICHD (p<0.001) or INHD patients (p<0.001). Weekly dialysis 
duration was lower in ICHD than SHD (633.7 vs. 803.4 minutes, p=0.001), lower in SHD 
than INHD (803.4 vs. 1148.5 minutes, p<0.001) and lower in INHD than FNHD (1148.5 
vs. 2128.1 minutes, p<0.001). Weekly ultrafiltration volume was lower in ICHD and 
INHD than SHD (6.5 and 6.6 vs. 10.4 L, p<0.001 and p=0.004) and lower in ICHD and 
INHD than FNHD (6.5 and 6.6 vs. 12.0 L, p<0.001 for both). 
Sodium setpoint decreased in FNHD patients when all pre-dialysis sodium 
concentrations from 100 days post-transition onwards were considered (PRENA-50 > 
PRENA100+)(138.5 to 136.7 mM, p=0.015)(Figure 3.2).  
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FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional 
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily 
hemodialysis. 
 
Figure 3.2: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between  
        Days 100 to 150 After (PRENA100-150) and All Days from 100 days After 
       (PRENA100+) Transition to Home Hemodialysis 
In both SHD and FNHD patients whose pre-transition pre-dialysis sodium 
(PRENA-50) was greater than or equal to the dialysate sodium of 140 mM, sodium 
setpoint decreased when post-transition pre-dialysis sodium concentrations from 100 
days onwards were considered (PRENA-50 > PRENA100+) (SHD 140.2 to 138.7 mM, 
p=0.019; FNHD 140.5 to 137.1 mM, p=0.001) (Figure 3.3). When pre-dialysis plasma 
sodiums were restricted to post-transition days 100 to 150, the sodium setpoint still 
decreased in both SHD and FNHD patients (SHD 140.2 to 138.6 mM, p=0.030; FNHD 
140.5 to 138.0 mM, p=0.008) (Figure 3.3). 
There was no difference in any dialysis modality group, between PRENA-50 and 
PRENA100+, or between PRENA-50 and PRENA100-150, if the pre-transition pre-
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dialysis sodium (PRENA-50) was less than the dialysate sodium concentration of 140 
mM (Figure 3.4). 
FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional 
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily 
hemodialysis. 
 
Figure 3.3: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between  
       Days 100 to 150 After (PRENA100-150) and All Days From 100 Days After       
       (PRENA100+) Transition to Home Hemodialysis, with Pre-Transition  
       Setpoint > 140 mmol/L 
The slope of pre-dialysis plasma sodium in the first 100 days post-transition 
(M100) was less than zero in all SHD (95% CI, -0.0055 to -0.0318 mM/day) and FNHD 
(95% CI, -0.0010 to -0.0394 mM/day) patients, and in SHD (95% CI, -0.0081 to -0.0351 
mM/day) and FNHD (95% CI, -0.0209 to -0.0695 mM/day) patients whose pre-transition 
pre-dialysis sodium (PRENA-50) was greater than or equal to 140 mM (Figure 3.5). 
Univariate regression analysis was performed to predict M100 using 73 data-sets 
from 29 SHD, 9 ICHD, 24 FNHD and 11 INHD patients. Univariate correlation 
coefficients and p values are shown (Table 3.2). The strongest predictor of M100 was the 
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dialysate to pre-dialysis plasma sodium difference (DPRENA-50)(R2 = 12.65%) although 
no independent factor reached statistical significance (Table 3.1). 
 
FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional 
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily 
hemodialysis. 
 
Figure 3.4: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between  
       Days 100 to 150 After (PRENA100-150) and All Days From 100 Days After  
       (PRENA100+) Transition to Home Hemodialysis, With Pre-Transition      
       Setpoint < 140 mmol/L 
 Univariate regression analysis was performed to predict DeltaPRENA100 and 
DeltaPRENA100-150 using 82 data-sets from 29 SHD, 13 ICHD, 28 FNHD and 12 
INHD patients. Univariate correlation coefficients and p values are shown (Table 3.2). 
The covariate of (DPRENA-50)(dialysis time) had a correlation of 31.8% and 42.0% for 
DeltaPRENA100 and DeltaPRENA100-150, respectively. However, this was entirely due 
to the DPRENA-50 component; elimination of dialysis duration from the covariate 
improved the correlation coefficient and p value in both DeltaPRENA100 (R2 = 31.8 to 
32.8%, p = 0.540 to 0.030) and DeltaPRENA100-150 (R2 = 42.0 to 42.0%, p = 0.859 to 
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0.002). Dialysis frequency (R2 = 6.19%, p = 0.060) and dialysis duration (R2 = 2.15%, p 
= 0.085) trended towards a relationship with DeltaPRENA100. 
A multivariate model was created to investigate the association of 
DeltaPRENA100 with dialysis frequency and DPRENA-50. 
 
Model 1 
DeltaPRENA100 = 0.4765 (DPRENA-50)  
- 0.3506 (dialysis frequency per week) – 0.2807 
R2   =  35.44% (adjusted R2 = 33.8%) 
F-statistic = 21.68 (on 2 and 79 degrees of freedom, p<0.001)   
DeltaPRENA100 =  (Post100-Na+) – (PRENA-50) 
DPRENA-50  = (Dialysis Na+) – (PRENA-50),  
adjusted p value < 0.001, R2 = 32.8% in univariate model 
Dialysis frequency  =  Dialysis sessions per week,  
adjusted p value = 0.077, R2 = 6.2% in univariate model 
 
 
Table 3.2: Univariate Regression Coefficients and P values for Independent Variables  
Predicting Slope of Predialysis Na+ in first 100 days (M100), Difference in 
Pre and Post-100 Days Post-Transition Pre-Dialysis Na+ (DeltaPRENA100+) 
and Differences in Pre- and Days 100-150 Post-Transition Pre-Dialysis Na+ 
(DeltaPRENA100-150) 
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3.4 Discussion 
The sodium setpoint is considered to be stable in hemodialysis patients. The results of 
this study suggest that this is true at least with ICHD. According to model 1, this 
assumption is reasonable in ICHD patients; a pre-dialysis sodium between 133.0 and 
141.0 mmol/L would be associated with DeltaPRENA100 between -2 and 2 mmol/L. 
This difference could be attributed to changes in total body water, or to laboratory 
measurement variability. In Keen and Gotch’s initial description of the stability of the 
pre-dialysis sodium setpoint,3 89% of patients had an average pre-dialysis plasma sodium 
from 133.0 mM to 141.0 mM.   
 
FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional 
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily 
hemodialysis. 
 
Figure 3.5: Slope of Pre-Dialysis Plasma Sodium Concentration, in First 100 Days After  
Transition from Conventional Thrice Weekly (ICHD) to Home Hemodialysis 
for All patients, and for Patients with Initial Sodium Setpoint (SP) > or < 140 
mmol/L 
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However, there are scenarios in which a sodium setpoint change may occur on the 
basis of model 1. Patients whose dialysate sodium is personalized to be equal or less than 
pre-dialysis sodium may decrease their sodium setpoint. For example, in a patient 
dialyzed 5 times weekly, with a pre-dialysis plasma sodium of 135 mmol/L, whose 
dialysate sodium is personalized to 132 mmol/L, in an attempt to “desalt,” the associated 
DeltaPRENA100 would be -3.5 mmol/L (model 1), which would bring the pre-dialysis 
plasma sodium setpoint down to 131.5 mmol/L, a level associated with increased 
mortality.16,17 
Furthermore, patients dialyzed in units using a “standard dialysate sodium 
concentration” may increase their pre-dialysis plasma sodium setpoint. For example, a 
patient dialysed 3 times weekly, with a setpoint of 130 mmol/L, whose dialysate sodium 
is 140 mmol/L would have an associated DeltaPRENA100 of +3.4 mmol/L (model 1), 
setting the new pre-dialysis plasma sodium setpoint to 133.4 mmol/L. These patients 
would not have been observed in the Keen and Gotch’s description, since none of their 
patients had sodium setpoints under 131 mmol/L. It is unknown whether the increased 
interdialytic weight gain observed in patients with a large dialysate to pre-dialysis plasma 
sodium difference, is offset by any improvement in mortality by increasing the sodium 
setpoint. If so, this may in part explain the unexpected results of Hecking et al, 15,19 who  
discovered that patients whose pre-dialysis sodium was less than 137 mmol/L had 
improved mortality when dialyzing against a higher dialysate sodium concentration, and 
reduced hospitalization and mortality with higher dialysate sodium concentrations, in 
units that did not individualize dialysate sodium concentrations. Dialysate sodium 
prescriptions may have changed some of the pre-dialysis sodium concentrations from a 
low level to a level associated with improved mortality. Prospective trials should evaluate 
the effect of intentionally increasing pre-dialysis plasma sodium setpoints, on 
cardiovascular and all-cause mortality. 
Determining the pathophysiology of a change of plasma sodium setpoint is not the 
objective of this study, and will need to be established prospectively. Stability in blood 
glucose, lipid and paraprotein concentrations needs to be initially assumed. Then if a 
patient has a pre-dialysis plasma sodium concentration greater than the dialysate sodium 
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concentration, one could hypothesize that the post-dialysis plasma sodium concentration 
would decrease towards the dialysate sodium concentration, since sodium loss would 
occur relative to the isosmotic ultrafiltration, leaving the plasma with relative sodium to 
water loss. It is possible that equilibration back to sodium setpoint homeostasis requires 
an interdialytic interval longer than patients on quotidian, but not intermittent 
hemodialysis modalities. This hypothesis would need to be evaluated prospectively. 
However, this would explain why adding (dialysis time) to (DPRENA-50) did not 
improve (DPRENA-50) prediction of DeltaPRENA100 (Table 3.2), since dialysis 
frequency is a much greater determinant of interdialytic interval duration. For example, 
doubling a patient’s dialysis duration from 4 to 8 hours (at dialysis frequency 3 times a 
week) only marginally decreases interdialytic time interval from 39.0 to 36.0 hours, 
whereas doubling a patient’s dialysis frequency from 3 to 6 weekly sessions (at dialysis 
duration 4 hours a session) significantly decreases interdialytic time interval from 39.0 to 
20.6 hours. Indeed, a patient with a pre-dialysis plasma sodium setpoint of 140 mmol/L, 
dialyzing 7 days weekly with a dialysate sodium of 140 mmol/L, would decrease their 
pre-dialysis plasma sodium setpoint to 137 mmol/L; this is a surprising and unexpected 
finding, the etiology of which will need to be elucidated with prospective investigations. 
Finally, quotidian dialysis therapies appear from these results to be associated 
with an increased chance of decreasing the sodium setpoint when the initial pre-dialysis 
plasma sodium setpoint is equal to or greater than the dialysate sodium (Figure 3.3). For 
example a patient on 6 nights a week hemodialysis, with an initial pre-dialysis plasma 
sodium of 143 mmol/L, and a dialysate sodium concentration of 140 mmol/L will have a 
DeltaPRENA100 of -3.8, bringing the pre-dialysis plasma sodium setpoint to 140.2 
mmol/L. Targeting the dialysate sodium concentration to below the pre-dialysis sodium 
setpoint could lead to repeated drops in the pre-dialysis sodium with every change in 
dialysate concentration. This may be undesirable from an outcome perspective.  
Any statistically significant changes in pre-dialysis plasma sodium setpoint were 
observed with 150 days after transition from thrice weekly conventional to home 
hemodialysis (Figure 3.3). It is thus unlikely that any decreases in pre-dialysis sodium 
setpoint related to patients developing comorbidities associated with lower plasma 
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sodium concentrations such as heart or liver disease. Indeed, the strongest associations 
with change in plasma sodium setpoint were iatrogenic, specifically the choices of 
dialysis frequency and the dialysate sodium to pre-dialysis plasma sodium difference 
(Table 3.2). Furthermore, only outpatient blood tests were considered, so acute illness or 
comorbid illness is unlikely to be a confounding factor. 
In light of numerous studies that suggest personalizing dialysate sodium 
concentrations can decrease interdialytic weight gain,6-13 these data give reason for 
caution. If dialysate sodium is intentionally decreased to the pre-dialysis plasma sodium 
concentration, the IDWG may fall, but any benefit in morbidity and mortality may be 
offset by a decrease in sodium setpoint.  
There are weaknesses to this study. Firstly, all data in this study were 
retrospective and measurements did not occur at exact time intervals in all patients. Thus, 
it remains unclear whether any change in sodium setpoint is a continuous process, or if 
any change is upon initiation of dialysis and complete after a short interval of time. 
However, the pre-dialysis plasma sodium setpoint change was completed within 150 days 
in our study, suggesting that patients reach a new “steady state” in which the effects of 
dialysis frequency and dialysate to pre-dialysis plasma sodium difference offset each 
other. Secondly, data points used were aggregates of variable numbers of dialysis and 
laboratory values occurring between variable time periods. This may explain why model 
1 only provides 35% explanation for the change in DeltaPRENA100. Thirdly, there were 
baseline differences between dialysis modality groups, such as residual renal function and 
patient weight, which may be confounders.  The study also has strengths in that numerous 
pre-dialysis plasma sodium values are available and that modalities differing in frequency 
and duration were used with this home hemodialysis population. While the sample size of 
patients was small (n=87), the findings were statistically significant and likely of clinical 
importance. 
Further studies are indicated in quotidian hemodialysis patients that will vary 
prospectively the dialysate sodium to establish the effect of dialysate sodium and sodium 
setpoint on cardiovascular morbidity and all cause mortality.  
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3.5 Conclusions 
In hemodialysis patients, the pre-dialysis plasma sodium “setpoint” is dynamic and 
correlated to the dialysate sodium concentration and dialysis frequency. Nephrologists 
should consider how the selected dialysate sodium concentration affects the dialysate to 
pre-dialysis plasma sodium concentration difference, and should also continue to monitor 
pre-dialysis plasma sodium concentrations. Prospective trials are needed to establish 
when the benefits of a decrease in interdialytic weight gain are offset by a decrease in 
sodium setpoint, and how dialysate sodium concentration should be targeted to minimize 
cardiovascular and all-cause mortality.  
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Chapter 4: Pre to Post-Dialysis Plasma Sodium Change Better Predicts Clinical 
Outcomes Than Dialysate to Plasma Sodium Gradient in Quotidian Hemodialysis. 
 
 
 
 
 
 
 
This chapter has been published as:  
Thomson BK, Huang SH, Leitch RE, et al. Pre to post-dialysis plasma sodium change 
better predicts clinical outcomes than dialysate to plasma sodium gradient in quotidian 
hemodialysis. Hemodial Int. Oct 2013;17(4):548-556. 
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4.1 Introduction 
The amount of sodium removed from a patient on hemodialysis is the sum of convective 
loss and the diffusive gain or loss on dialysis.1 Diffusive sodium balance on thrice weekly 
intermittent conventional hemodialysis (ICHD) is associated with important clinical 
outcomes, including interdialytic weight gain (IDWG), blood pressure, intradialytic 
hypotension, cardiovascular morbidity and mortality.2-6    Which aspect of sodium balance 
is best to follow (and perhaps influence) is controversial; while decreasing dialysate 
sodium decreases thirst, IDWG and blood pressure,1-8post-dialysis minus pre-dialysis 
plasma sodium (PPNa+) may be superior to dialysate sodium minus pre-dialysis plasma 
sodium (DPNa+) in predicting mortality.6 
While the effects of PPNa+ and DPNa+ in ICHD have been reported, those in 
more frequent dialysis modalities remain unknown. The objective of this study was to 
determine whether DPNa+ or PPNa+ better predicted clinical outcomes in patients on 
short hours daily (SHD) and frequent nocturnal home hemodialysis (FNHD) and to  
define these outcomes in FNHD and SHD. 
4.2 Materials and Methods 
All patients who received treatment through the Southwestern Ontario Regional Home 
Hemodialysis program base in London Ontario, from 1985 to December 31, 2011 were 
considered (n=101). A retrospective observational study was used. Patients were required 
to be on an assigned dialysis modality for a minimum of 120 days, to facilitate adequate 
record collection (n=92). All patients included in this trial initiated home hemodialysis 
after January 1, 1998. Patients who were on either short hours daily (SHD) (n=35) or 
frequent nocturnal hemodialysis (FNHD) (n=38) were included. Intermittent 
conventional hemodialysis (ICHD) (n=11) and intermittent nocturnal hemodialysis 
(INHD) (n=8) patients were excluded because of their low numbers.  
Dialysis Modality and Characteristics 
SHD home (n=35) was defined as a minimum of 5 treatments per week, with a minimum 
treatment time of 1.5 hours and a maximum treatment time of 4.0 hours. FNHD home 
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(n=38) was defined as a minimum of 5 treatments per week, with a minimum treatment 
time of 6.0 hours.  
Dialysate sodium concentration was 140 mmol/L for all patients. Dialysate 
bicarbonate and potassium concentrations were personalized for each patient, to 
normalize pre-dialysis potassium and bicarbonate concentrations. Dialysate calcium 
concentration was 1.25 mEq/L for all SHD patients. From December, 2001 onwards, all 
FNHD patients dialyzed using a 1.75 mEq/L Ca++ dialysate concentration, as is now 
considered standard practice.9 Prior to December, 2001, patients’ dialysate calcium 
concentration was either 1.25 or 1.75 mEq/L. Thus, the majority of FNHD patients 
(26/38, 68.4%) used a dialysate calcium concentration of 1.75 mEq/L for the entire 
duration of this trial, and for those patients who initiated home hemodialysis prior to 
December 2001, 40.6% of data were collected while dialysate calcium concentration was 
1.75 mEq/L. 
Blood sample collection 
Pre and post-dialysis blood samples are routinely taken each month. Home patients are 
trained to take blood from the arterial blood line at the start of dialysis and post-dialysis, 
using a standard slow blood and stop dialysate method. The samples are centrifuged and 
then stored and refrigerated until delivered to the local laboratory for that patient. All 
patient blood tests are measured using automated and standardized methods. Of interest 
to this study were pre-dialysis plasma sodium, bicarbonate and albumin, and post-dialysis 
plasma sodium values.  
Sodium concentration measurement 
Plasma sodium concentration was measured using Beckman-Coulter LX20 Pro 
Chemistry Analyzer with Ion Selective Electrodes prior to, and Roche Modular P 
Chemistry Analyzer with Ion Selective Electrodes after November 4, 2008. 
Dialysate sodium concentration was determined using online conductivity 
measurements built into the Fresenius H series hemodialysis machine, which was used 
for all patients.  
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Database Creation 
Blood test results were obtained from the hospital electronic patient record (PowerChart 
by Cerner). Data from individual patients were only used in the study if a minimum of 3 
pre- and post-dialysis plasma sodium sets were available.  
IDWG, pre and post-dialysis systolic and diastolic blood pressures, dialysis 
treatment times, and ultrafiltration volumes were obtained from archived dialysis 
treatment run sheets. These were the defined outcomes. The average values for these per 
month were calculated and entered into the study database. Summary measures were used 
at the patient level to avoid issues of correlation within patients.  As such, a single value 
representing the average monthly value for each outcome per person was used in the 
analyses regardless of patient hemodialysis vintage.  
Demographic patient information, including age, sex, weight (kg) at initiation of 
therapy, presence of diabetes, months of renal replacement therapy prior to initiation of 
home hemodialysis, and date of initiation of home hemodialysis were recorded by chart 
review. The blood pressure before initiation of home hemodialysis was recorded from the 
pre-home hemodialysis assessment clinic, which is within 1 month of initiation.  
Residual glomerular filtration rate at initiation of home hemodialysis (Kr in 
mL/min/1.73m2), was calculated using 24 hour urine collections for urinary urea and 
creatinine, as previously described.10 Residual urinary volume was not commonly 
recorded, and thus residual renal function was used instead. Patients who urinated less 
than 250 mL urine daily were recorded to have no residual renal function. 
Ethics 
Because of concerns regarding the use of a standard dialysate of 140 mmol/L sodium 
concentration and prompted by the observation of high IDWGs in patients undergoing 
FNHD, a quality assurance investigation was instituted.  All laboratory tests had been 
taken as per routine care protocols; demographic and dialysis treatment information were 
available from patient records.  Once extracted, all data were de-identified before 
analysis.  No patient had to provide blood samples, answer questionnaires or do anything 
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specific for this study that was conducted in accordance with the Declaration of Helsinki.  
Thus, informed written consent was not obtained from the current patients.   
Statistics 
Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 
19.0. The average for all demographic factors was calculated. To compare FNHD and 
SHD patients at baseline, p-values were calculated using two tailed student t-test for 
continuous variables and Fisher’s exact test for categorical variables. Each baseline 
demographic and clinical factor’s distribution was assessed. When a non-normal 
distribution was found, that factor’s median and interquartile ranges were calculated.  
To evaluate which of DPNA or PPNA better predicted the clinical endpoints, 
univariable analyses using dependent variables of IDWG, pre-dialytic systolic and 
diastolic blood pressures, intradialytic change in systolic and diastolic blood pressures, 
and ultrafiltration rate were conducted SHD and FNHD patients were considered 
collectively, then separately. R2 and p-values were calculated, and a p-value of less than 
or equal to 0.05 was considered statistically significant. 
DPNa+ = dialysate minus pre-dialysis plasma sodium concentration; PPNa+ = Post- 
minus Pre-dialysis plasma sodium concentration. 
Table 4.1: Number of Observations for Pre- to Post Hemodialysis (PPNa+) and Dialysate  
      to Pre-Hemodialysis (DPNa+) Sodium Gradient, and for Each Clinical   
      Outcome 
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The mean, median, range, interquartile ranges and variance in the number of 
observations for DPNa+ and PPNa+, and for each clinical outcome, were calculated. The 
effects of DPNa+ and PPNa+ on IDWG, pre-dialytic systolic and diastolic blood 
pressures, intradialytic change in systolic and diastolic blood pressures, and ultrafiltration 
rate were compared between SHD and FNHD using two tailed student t-tests. Statistical 
significance was considered at p ≤ 0.05. 
4.3 Results 
A total of 73 sets of time-averaged pre- and post-dialysis plasma sodium values were 
made from 2065 matched pre- and post-dialysis plasma sodium values. There were a 
mean and median number of 28.3 and 16.0 observations for each patient’s PPNa+ and 
41.1 and 27.0 observations for each patient’s DPNa+ (Table 4.1). The majority of all 
patients combined (90.4%), and each of SHD (88.6%) and FNHD (92.1%) had pre-
dialysate plasma sodium values less than the dialysate sodium of 140 mmol/L(Figure 
4.1). The majority of all patients combined (96.5%) and each of SHD (97.1%) and FNHD 
(94.7%) had post-dialysis plasma sodium levels less than the dialysate sodium of 140 
mmol/L (Figure 4.2).  
There were a mean and median of 13.1 and 8.0 observations for each patient’s 
IDWG, 12.9 and 8.0 observations for each patient’s paired pre and post hemodialysis BP, 
and 13.5 and 8.0 observations for each patient’s ultrafiltration volume (Table 4.1). 
All background demographic and clinical factors had a normal distribution (Table 
4.2), except for residual renal function (mL/min) and vintage of renal replacement prior 
to initiation of home hemodialysis (months). The mean, median and first to third 
interquartile ranges for dialysis vintage (months) were 67.0, 50.0 and 18.0 to 102.0 for 
SHD and 94.5, 71.0, and 24.0 to 121.0 for FNHD. The mean, median and first to third 
interquartile ranges for residual renal function (mL/min) were 0.47, 0.00 and 0.00 to 0.00 
for SHD and 0.78, 0.00, and 0.00 to 0.84 for FNHD.  
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FNHD = frequent nocturnal hemodialysis; SHD = short hours daily hemodialysis 
Figure 4.1 Pre-Dialysis Plasma    Figure 4.2: Post-Dialysis Plasma 
      Sodium Concentration            Sodium Concentration 
 
SHD patients had a slightly higher dialysis frequency (Table 4.2) (5.54 vs. 5.26 
sessions per week, p=0.03), and as expected, a lower dialysis duration (146.0 vs. 402.8 
minutes, p<0.001) than FNHD patients.  
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Table 4.2: Demographic and Clinical Factors of Patients on Short Hours Daily and  
      Frequent Nocturnal Home Hemodialysis 
PPNa+ was superior to DPNa+ in predicting IDWG (Table 4.3) in SHD patients 
(R2 = 0.105 vs. 0.019, p=0.04 vs. 0.68), FNHD patients (R2 = 0.223 vs. 0.020, p=0.002 
vs. 0.76) and combined (R2 = 0.147 vs. 0.024, p=0.001 vs. 0.75). PPNa+ was superior to 
DPNa+ in predicting pre-dialysis systolic blood pressure in SHD patients (R2 = 0.103 vs. 
0.007, p = 0.02 vs. 0.82). PPNa+ was superior to DPNa+ in predicting intradialytic 
change in systolic BP in FNHD patients (R2 = 0.100 vs. 0.002, p=0.02 vs. 0.16) and 
combined patients (R2 = 0.042 vs. 0.015,  p = 0.002 vs. 0.02). PPNa+ was superior to 
DPNa+ in predicting intradialytic change in diastolic BP in FNHD patients (R2 = 0.066 
vs. 0.019, p = 0.02 vs. 0.06) and combined patients (R2 = 0.014 vs. 0.060, p=0.004 vs. 
1.0). PPNa+ was superior to DPNa+ in predicting ultrafiltration rate in FNHD patients  
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DPNa+ = Dialysate minus Pre-dialysis plasma sodium concentration; FNHD = frequent 
nocturnal hemodialysis; PPNa+ = Post- minus Pre-dialysis plasma sodium concentration; 
SHD = short hours daily hemodialysis 
Table 4.3: PPNa+ and DPNa+ Versus Clinical Outcomes in Short Hours Daily and  
      Frequent Nocturnal Hemodialysis 
(R2 = 0.296 vs. 0.036, p = 0.001 vs. 0.52) and combined patients (R2 = 0.038 vs. 0.003, p 
= 0.05 vs. 0.73).  
DPNa+ was superior to PPNa+ in predicting intradialytic change in diastolic BP 
in SHD patients (R2 = 0.101 vs. 0.003, p=0.02 vs. 0.13). No other statistically significant 
differences were found between DPNa+ and PPNa+, for any clinical endpoints.  
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Ultrafiltration rate was significantly lower in FNHD than SHD patients (0.035 vs. 
0.77 L/hour, p < 0.001) (Table 4.4). While IDWG appeared higher in FNHD than in SHD 
patients (2.25 vs. 1.92 L), this approached but did not reach statistical significance 
(p=0.06). There were no other statistically significant differences in clinical outcomes 
between SHD and FNHD patients. 
Table 4.4: Clinical Endpoints of Standardized Dialysate Bath of 140 mmol/L in Short  
      Hours Daily Versus Frequent Nocturnal Hemodialysis Patients 
PPNa+ correlated with increased interdialytic weight gain in both SHD and 
FNHD patients, but this correlation was stronger in FNHD patients (R2 = 0.105 vs. 
0.019), with greater statistical significance (p = 0.04 vs. 0.68) and with greater slope 
(0.166 vs. 0.134) (Figure 4.3).  
In FNHD patients, PPNa+ associated with greater drops in systolic (slope= -
1.847, R2 = 0.100, p = 0.02) and diastolic (slope = -0.866, R2 = 0.066, p = 0.02) blood 
pressures on dialysis (Figure 4.4). This was in contrast to SHD patients, in whom a 
greater DPNa+ associated with a decreased drop of diastolic blood pressure (slope 
=0.786, R2 = 0.101, p=0.02) (Table 4.3).  This is shown graphically (Figure 4.4); as post-
dialysis plasma sodium increases relative to pre-dialysis plasma sodium in FNHD 
patients, there is more of a drop in systolic and diastolic blood pressures on dialysis. On 
the other hand, as dialysate sodium increases relative to pre-dialysis plasma sodium in 
SHD patients, the magnitude of diastolic blood pressure fall on dialysis decreases. 
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Figure 4.3: Effect of PPNa+ on Interdialytic Weight Gain for Short Hours Daily and  
        Frequent Nocturnal Hemodialysis Patients 
4.4 Discussion 
Total sodium balance on hemodialysis is determined by the net of convective loss and 
diffusive sodium gain or loss.1 Positive sodium balance in patients on thrice weekly 
conventional hemodialysis is associated with IDWG, and, in turn hypertension, left 
ventricular hypertrophy and cardiovascular morbidity and mortality.1,5-8,13 Both low and 
high pre-dialysis systolic blood pressures are associated with increased mortality in 
patients undergoing thrice weekly hemodialysis. However, the clinical effects of more 
frequent and longer duration exposure to a dialysate higher than the pre-dialysis plasma 
sodium has not been described.  
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Figure 4.4: Intradialytic Change in Blood Pressure in Short Hours Daily and Frequent  
        Nocturnal Hemodialysis Patients  
Understanding which of DPNa+ or PPNa+ better predicts clinical outcomes is 
important not only in determining which factors are modifiable, but also to design 
prospective trials aimed at improving outcomes. Reducing dialysate sodium has been 
shown to improve IDWG and blood pressure,1,3-7and DPNa+ has been correlated to 
IDWG.16 However, in large population observational data, PPNa+ appears superior to 
DPNa+ in predicting IDWG in ICHD.17 Our study confirms that in quotidian dialyzed 
patients, PPNa+ has a stronger association than  DPNa+ with IDWG, intradialytic change 
in blood pressure, and ultrafiltration rates, consistent with recent work of Hecking et al.17 
IDWG was more strongly correlated to PPNa+ in FNHD than SHD patients (R2=0.223 
vs. 0.105), and with greater statistical significance (p=0.002 vs. 0.04) and slope (0.166 vs. 
0.134) (Table 4.3) (Figure 4.3). This reflects the longer exposure to a positive diffusive 
difference (402.8 vs. 146.0 minutes, p < 0.001) (Table 4.2). This is consistent with the 
recent work of Munoz-Mendoza et al, who showed decreased IDWG and blood pressure 
in thrice weekly nocturnal patients exposed to lower dialysate sodium concentrations.18 
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DPNa+ was more correlated than PPNa+ with intradialytic change in blood 
pressure, in SHD patients. This was the only clinical variable associated more with 
DPNa+ than PPNa+. This was in contrast to FNHD patients, where PPNa+ was more 
associated with change in BP on dialysis, only in the opposite direction (Figure 4.4). This 
may result from a variety of factors. Firstly, FNHD patients are exposed to a diffusive 
difference longer and thus have a more positive sodium balance. While the higher IDWG 
in FNHD patients in our trial did not reach statistical significance (2.25 vs. 1.92 L, 
p=0.06)(Table 4.4), patients in the London Daily Nocturnal Dialysis Study with a 
dialysate sodium of 140 mM had higher IDWG in FNHD vs. SHD patients. This may 
cause the intradialytic change in blood pressure to reflect relative ultrafiltration 
requirements, which are higher with more positive sodium balance (Table 4.3). Secondly, 
it’s possible that the recumbent position of FNHD patients has different effects on the 
effective circulating volume (ECV), and that time upright is needed before this 
approximates the ECV of SHD patient undergoing ultrafiltration of a similar volume. 
Finally, FNHD patients may have greater restoration in homeostasis of hormones 
involved in blood pressure regulation. The generation of intradialytic hypotension is 
associated with autonomic neuropathy17which may be improved by nocturnal dialysis 
modalities.20 
Intradialytic hypotension is associated with increased mortality in patients 
undergoing thrice weekly hemodialysis.20 However, the increased intradialytic drop in 
blood pressure in FNHD patients with an increased PPNa+ is of uncertain clinical 
significance. FNHD patients are on less anti-hypertensive medications than SHD patients, 
and suffer from fewer dialysis related symptoms like cramping, headaches, dizziness, 
dyspnea, and self-reported intradialytic hypotension.22 The study provides clinically 
important information. Firstly, the majority of quotidian patients (90.4%) are exposed to 
a positive diffusive difference for sodium (Figure 4.1). Ideally, this dialysate sodium 
should be targeted to minimize IDWG, to improve blood pressure and to minimize risk of 
intradialytic hypotension. This can be achieved by personalizing the dialysate sodium so 
that PPNa+ is zero or even slightly negative. This effect appears more crucial in FNHD 
than SHD patients, because of the longer duration of therapy. Furthermore, a negative 
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DPNa+ or PPNa+ does not seem to predispose FNHD patients to the risk of intradialytic 
hypotension as it does in SHD patients.  
This study does have limitations. A relatively small number of patients of variable 
dialysis vintage were studied in a retrospective fashion. All data points were aggregates 
of variable numbers of dialysis and laboratory values, occurring between variable time 
periods, corresponding to patients’ attendance at clinics, when data were entered into the 
electronic patient record. However, numerous pre- and post-dialysis sodium values were 
available from two quotidian dialysis modalities. The active plasma sodium available for 
diffusion could not be quantified precisely in this study. However, the concentration of 
major plasma anions albumin and bicarbonate were not statistically different pre-dialysis 
(Table 4.2), suggesting that the Gibbs-Donnan effect23 did not operate disproportionately 
in one dialysis modality. 
In conclusion, the PPNa+ has a greater association than DPNa+ to IDWG, pre-
dialysis systolic blood pressure, intradialytic blood pressure change and ultrafiltration 
rates in SHD and FNHD patients. However, DPNa is associated with intradialytic 
diastolic blood pressure change in SHD, but not in FNHD patients.  In the latter, a 
positive sodium balance increases the risk of large blood pressure drops on dialysis. 
Further work is needed to establish the effect of altering dialysate sodium concentration, 
on long-term cardiovascular outcomes, in quotidian dialyzed patients.  
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Chapter 5: Modifiable Variables Affecting Interdialytic Weight Gain Include 
Dialysis Time, Frequency, and Dialysate Sodium. 
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5.1 Introduction 
Intradialytic sodium (Na+) removal leads to decreased blood pressure1-3 and decreased 
interdialytic weight gain (IDWG).4-8 This may lead to better outcomes9 in hemodialysis 
patients, although this is controversial.12 The amount of Na+ removed from a patient 
during hemodialysis is the net of that lost by convection with that lost or gained by 
diffusion.4 Diffusive gain occurs when the dialysate Na+ exceeds the pre-dialysis plasma 
Na+. In the London Daily Nocturnal Dialysis study,10 IDWG was higher in frequent 
nocturnal (FNHD) than short hours daily hemodialysis (SHD) patients, using a standard 
dialysate concentration of 140 mmol/L, suggesting that the time of exposure to a higher 
dialysate Na+ may affect IDWG. In contrast, the Frequent Hemodialysis Network 
(FHN)11 showed less IDWG in FNHD patients but they had variable dialysate Na+ 
concentrations and higher urinary volumes. Thus, factors that determine IDWG may 
include residual urinary volume, dialysis time and frequency, and the dialysate to plasma 
diffusion difference (DPNa+). A recent study determined that pre to post dialysis change 
in plasma Na+ (PPNa+) better correlated to clinical outcomes than did the δDPNa+.8 
However, the effect of DPNa+ on mortality remains controversial, with one large 
prospective cohort study showing positive DPNa+ associated with decreased mortality,12 
contrary to the findings of previous studies.13 However, PPNa+ is likely the result of both 
DPNa+ and time of exposure to the diffusive Na+ difference.   
The study objective was to derive an equation, using multivariable regression 
analysis, of modifiable variables that affect IDWG.  
5.2 Materials and Methods 
Study Population 
All patients in the home hemodialysis program of the Southwestern Ontario Regional 
Renal Program, from February 11, 1998 to December 1, 2012, were included, using a 
retrospective observational design.  
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Dialysis Modality 
Modality was defined by the duration of dialysis and its frequency.  SHD implied a 
minimum of 5 weekly treatments with treatment times of 1.5-4.0 hours. Intermittent 
conventional hemodialysis (ICHD) meant a maximum of 4 weekly treatments and times 
between 3-5 hours.  FNHD indicated a minimum of 5 weekly treatments of 6.0 hours or 
more. Dialysate Na+ concentration was always 140 mmol/L. When patients changed 
dialysis modality during the observation period, only the first dialysis modality was 
considered.  
Blood sample collection 
Pre and post dialysis blood samples are taken each month from the arterial blood line 
using a standard slow blood and stop dialysate method. Locking solution (3 mL 4% 
citrate) and a small amount of blood (2 mL) are always spent before blood is collected. 
The samples are centrifuged, stored and refrigerated until delivered to the laboratory. Of 
interest to this study were pre and post-dialysis plasma Na+ and pre-dialysis albumins, 
measured using automated and standardized methods. Only outpatient blood tests were 
used, to assure that the patient was at their baseline health status, so that the plasma Na+ 
concentration would not be confounded by acute illness. 
Na+ concentration measurement 
Plasma Na+ concentration was measured using Beckman-Coulter LX20 Pro Chemistry 
Analyzer with Ion Selective Electrodes prior to, and Roche Modular P Chemistry 
Analyzer with Ion Selective Electrodes after November 4, 2008. This change was made 
by the London Health Sciences Center because of a need for higher volume of laboratory 
testing. Both plasma Na+ concentration methods were regularly calibrated; thus, the 
measurements were treated as equivalent on data analysis. Dialysate Na+ concentration 
was determined using online conductivity measurements built into the Fresenius H series 
hemodialysis machine, which was used for all patients. Blood glucose was not measured 
simultaneous to Na+ concentration; thus, plasma sodium levels were not corrected for 
glucose. 
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Database Creation 
Blood test results were available from the hospital electronic patient record (Power Chart 
by Cerner). IDWG and dialysis treatment times were obtained from dialysis treatment run 
sheets. The average monthly values were calculated and entered into the database. For 
this analysis, a single value for each patient data point was used, being the average of the 
monthly values regardless of hemodialysis vintage. Demographic patient information, 
including age, sex, weight (kg) and height (cm) at initiation of therapy, diabetic status, 
and months of renal replacement therapy prior to initiation of home hemodialysis, were 
recorded by chart review. Residual glomerular filtration rate (ml/min x 1.73 m2) at 
baseline14 was recorded. Our home hemodialysis program does not perform urine 
collections if the 24 hour urine volume is less than 250 mL, since we have found that this 
amount only marginally contributes to weekly standard Kt/V. Thus, patients with less 
than 250 mL urine daily were recorded as having zero renal function. Once obtained, data 
was de-identified and then entered into the study specific database for analysis. 
Interdialytic Weight Gain 
IDWG was calculated as the difference between the post-dialysis body weight and the 
next dialysis session’s pre-dialysis body weight. A single IDWG value for each patient 
was entered into the database, being the average of the monthly values regardless of 
hemodialysis vintage. 
We chose to use interdialytic weight gain as an absolute value (IDWG), rather 
than as a percentage of body weight (IDWG%BW), for three reasons. Firstly, using all 
available clinical and demographic variables, the unadjusted correlation coefficient was 
higher for IDWG than IDWG%BW (R2 = 37.3% vs 32.2%). Secondly, on home 
hemodialysis run sheets, patients did not always record body weight simultaneous to 
IDWG, so there was temporal inaccuracy in IDWG%BW measurements. Thirdly, 
IDWG%BW was autocorrelated with age, diabetes status and PPNa+, each of which were 
important to assess in our final model. 
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Ethics 
Because of concerns regarding the use of a standard dialysate of 140 mmol/L Na+ 
concentration and prompted by the observation of high IDWGs in patients undergoing 
FNHD, a quality assurance investigation was instituted.  All laboratory tests had been 
taken as per routine care protocols; demographic and dialysis treatment information were 
available from patient records.  Once extracted, all data was de-identified before analysis.  
No patient had to provide blood samples, answer questionnaires or do anything specific 
for this study which was conducted in accordance with the Declaration of Helsinki.  
Thus, informed written consent was not obtained from the current patients.   
Statistics 
Two time periods were considered. Data prior to December 30, 2011 were used to 
determine the equation for IDWG, which was internally validated using bootstrapping. 
External validation used data from a temporally distinct population group, from August 1 
to December 10, 2012. 
Univariate analyses were used to investigate the relationship of each covariate 
with the dependent variables. Descriptive statistics and univariable analyses were 
conducted using the Statistical Package for Social Sciences (SPSS) version 19.0. 
Multivariable regression models were used to develop predictive models through 
backwards selection and a comparison of the adjusted Akaike Information Criterion 
(AIC) of nested models.15 Starting with a saturated model (containing all potential 
covariates) each independent variable starting with the largest p-value, was sequentially 
removed provided it did not meet the chosen liberal cut-off point for statistical 
significance i.e. a p-value > 0.10.  With each variable removed, the nested model was 
then compared to the previous model based on the corrected AIC value.  The model with 
the smallest AIC was chosen to be the best model.  If the corrected AIC value of the 
nested model was within 1% of the previous model, we considered the models equivalent 
and choose the more parsimonious model (fewer covariates).  The corrected AIC is 
calculated16 as: 
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corrected!!"# = 2! − 2 ln !"#$%"ℎ!!" + 2!(! + 1)! − ! − 1 !, 
 
                                   k = number of parameters  
         n  = number of observations and  
 ln !"#$%"ℎ!!"   = log-likelihood of the model 
Corrected AIC was chosen due to the small sample size.  Model fit was evaluated using 
F-statistic, R2 and adjusted R2 values.   
To establish which factors influenced the dependent variable IDWG, independent 
variables included PPNa+, dialysis time and frequency, patient age, sex, albumin, 
diabetes status, and residual renal function. Patient albumin was included in the model 
because of concerns regarding the Gibbs-Donnan effect.17 Model building was performed 
to build our first equation, and the F-statistic, R2 and adjusted R2 values were calculated 
for resulting model. 
To derive an equation defining IDWG, we used multivariable regression analysis. 
PPNa+ cannot be used as an independent variable since the post-dialysis plasma Na+ has 
to be known. We thus investigated the correlation of PPNa+ to diffusive balance of Na+, 
represented by the product of DPNa+ and dialysis time, using Pearson’s correlation 
coefficient.  A multivariable linear model was then developed leading to Equation 5.2.  
The F-statistic, R2 and adjusted R2 values were calculated.  
The final predictive model was validated using internal bootstrapping for both 
model selection and predictive qualities.18 Multivariable data analysis and bootstrap 
validations were conducted using the statistical software R version 2.14.1.19 Bootstrap 
validation was conducted by randomly sampling N=86 observations with replacement, to 
create the validation sample. Estimates of the residual standard error, mean square 
predictive error and mean residual value were calculated by fitting the bootstrap data to 
the final predictive model. For each bootstrap sample, we developed new linear models 
and estimated the regression coefficients and model properties.  This process was 
repeated for 1000 bootstrap samples and the average values of all estimates calculated.  
To evaluate the predictive properties of the final equation, the data from each of the 1000 
bootstrap samples were fit using the predictive model.   
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For external validation, we applied equation 5.2 to our current home hemodialysis 
patients and compared predicted with actual IDWGs. The variables required for the 
predicted were obtained from charts, electronic patient records and dialysis run sheets; 
data between August and December 2012 with at least 2 pre-dialysis blood sample results 
were taken, averaged and used in the equation 5.2. Actual IDWGs for each dialysis 
session in that same period were obtained from run sheets and averaged. Patients who 
were in the internal validation were excluded, leaving 24 new patients for the external 
validation. The distribution of dialysis modalities (8 SHD, 8 ICHD, 4 FNHD, 4 INHD) 
spanned all hemodialysis modalities. Predicted and actual IDWGs were compared by 
linear regression and Bland-Altman analyses.20  
Figure 5.1: Distribution of Pre-Hemodialysis Plasma Sodium Concentrations 
5.3 Results 
A total of 2868 matched pre and post-dialysis plasma Na+ values were available, giving 
86 sets of time-averaged patient pre and post-dialysis Na+ values (Figures 5.1 and 5.2), 
from SHD (n=32), ICHD (n=17) and FNHD (n=37) patients. The majority (87.2%, 
75/86) of the pre-dialysis plasma Na+ values were below the dialysate Na+ of 140 
mmol/L, while 16.3% (14/86) were below 135 mmol/L. Both pre-dialysis and post-
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dialysis plasma Na+ spanned at least the entire normal range (Table 5.1), with median 
values of 137.73 mmol/L and 137.37 mmol/L, respectively. 
Figure 5.2: Distribution of Post-dialysis Plasma Sodium Concentrations 
The mean, median, and standard deviation of all independent variables were 
calculated (Table 5.1), and the range spanned the range for most factors.  
DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Post- 
minus Pre-dialysis plasma sodium concentration 
 
Table 5.1: Demographic and Clinical Factors of Patients in  
      Multivariate Regression Model 
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DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Post- 
minus Pre-dialysis plasma sodium concentration 
 
Table 5.2: Univariate Regression Analysis of Interdialytic Weight Gain  
      in Home Hemodialysis 
Using univariable regression analysis for IDWG, the unadjusted p-values and 
correlation coefficients for independent factors were calculated (Table 5.2). PPNa+ 
(R2=20.36%, p<0.001), albumin (R2=9.35%, p=0.020), dialysis frequency (R2=1.74%, 
p=0.019) and female sex R2=1.28%, p=0.029) were significantly (p-value > 0.05, 
R2>1%) correlated to IDWG. Univariable regression analysis confirmed that PPNa+ was 
better than DPNa+ at predicting IDWG (R2 = 20.36% versus 6.66%, p<0.001 versus 
0.152).  
Equation 5.1 was calculated using multivariable regression analysis, and the same 
independent variables, to predict IDWG. Since DPNa+ was less effective at predicting 
PPNa+, only PPNa+ was used in our regression model for equation 5.1. 
 
Equation 5.1:  IDWG = 5.0694 + 0.17889(PPNa) – 0.1542(frequency) – 0.0145(Age)  
– 0.2316(if female) – 0.0457(Albumin) +0.001354 (Dialysis Time) 
Where  IDWG  = interdialytic weight gain, in liters 
PPNa+ = (plasma post-dialysis Na+)–(plasma pre-dialysis Na+),in mmol/L 
 Frequency = dialysis frequency, in sessions per week 
 Albumin = average patient albumin, in g/L 
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 Dialysis time = Dialysis session time, in minutes 
F-statistic  = 7.309 on 6 and 79 degrees of freedom (p-value < 0.001),  
R2   = 35.69% (adjusted R2 = 30.81%) 
Standard errors, p-values and 95% confidence intervals for the regression coefficient 
estimates are presented in Table 5.3. 
Since the post-dialysis plasma Na+ cannot be determined prior to dialysis, we 
correlated PPNa+ to the diffusive Na+ balance, represented by the product of DPNa+ and 
dialysis time (minutes). The Pearson correlation coefficient between PPNa+ and this 
product is 0.4054, suggesting a moderate correlation. In a simple linear regression model 
between PPNa+ and the product of (DPNa+) and dialysis time, there was an F-statistic of 
16.53 on 1 and 84 degrees of freedom, corresponding to a model p-value of <0.001. 
Given the product of DPNa+ and dialysis time was well correlated to PPNa+, a 
second equation was developed by fitting a multivariable linear regression model to 
IDWG. This second model included all independent variables from equation 5.1, except 
PPNa+, which was replaced by the covariate of (DPNa+) times dialysis time. Thus, 
equation 5.2 included factors that were all known prior to the dialysis session. 
 
Equation 5.2: IDWG = 5.8178 + 0.00023215 (DPNa+)(Dialysis time) – 0.0107(Age) 
- 0.1558(frequency) – 0.2977(if female) – 0.0654(Albumin)  
Where IDWG  = Interdialytic weight gain, in Liters 
DPNa+  = (Dialysate Na+) – (Pre-dialysis plasma Na+) 
Dialysis time = Dialysis session time, in minutes 
Frequency = dialysis frequency, in sessions per week 
Age  = years old, of patient 
 Albumin = average patient albumin, in g/L 
F-statistic  = 4.1940 on 5 and 80 degrees of freedom (p-value = 0.002),  
R2 =  20.77% (adjusted R2 = 15.82%) 
Standard errors, p-values and 95% confidence intervals for the regression 
coefficient estimates are presented in Table 5.3.  The parameter estimates obtained 
through the bootstrap sample were all normally distributed. The average (min, max) of 
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the residuals was 0.0055 (-0.2207, 0.2449); the average deviation of the bootstrap 
samples from the predictive value is close to 0.  The average bootstrap residual median 
was -0.0091, suggesting that the residuals may have been slightly skewed. The Root 
Mean Squared Error (RMSE) for equation 5.2 was 0.7208; this describes the discrepancy 
of observations and the estimated model. The bootstrap samples’ average Root Mean 
Squared Predictive Error was 0.7218; the predictive power is slightly reduced when 
fitting Equation 5.2 to the bootstrap samples.  The unadjusted R2 value for the bootstrap 
samples was 20.13%, close to the unadjusted R2 value (20.77%) in Equation 5.2.
 
DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Post- 
minus Pre-dialysis plasma sodium concentration 
 
Table 5.3: Multivariable Regression Analysis to Predict Interdialytic Weight Gain by  
      Equations 1 and 2 
The average R2 value (min, max) for the 1000 created models was 29.62% 
(4.80%, 65.85%) and an adjusted R2 of 24.92% (0.10%, 62.79%).  The average F-statistic 
value was 6.6521 on 5 and 80 degrees of freedom (average p-value = 0.005).  The 
average occurrence of variable selection is presented in Table 5.4; (DPNa+)(dialysis 
duration), sex, albumin and dialysis frequency were in over 80% of the bootstrap 
samples, while age, diabetes status and residual renal function (Kr) were in 74%, 73% 
and 41%, respectively.   The average regression coefficient estimates are also in table 4; 
the mean parameter estimates are close to those regression coefficients estimated in 
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Equation 5.2. The absolute bias for all covariates is less than 0.08 (except for the 
intercept, which shows an absolute bias of 3.3).  
The 95% confidence intervals for the bootstrap parameter estimates are also 
calculated; the confidence intervals for residual renal function and diabetic status include 
0, so these variables were not included in the model. The upper limit for age is close to 0, 
but we chose to leave Age in the model since it improved our predictive ability. The 
remaining covariates did not include 0 and thus reinforced their inclusion in the model. 
DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Post- 
minus Pre-dialysis plasma sodium concentration 
 
Table 5.4: Bootstrap Validation of Predictive Equation for  
      Interdialytic Weight Gain (Equation 2) 
A calibration plot was completed for the external validation cohort (n=24) (Figure 
5.3). There were 37 pre-dialysis plasma Na+ measurements available for the external 
validation cohort, an average and median of 1.54 and 1.00 for each patient, respectively. 
The distribution of IDWG for these patients was determined (Table 5.5), and spanned a 
wide range (0.39 to 3.16 liters), with a mean and median of 1.83 and 1.87 Liters. The x-
axis represents predictions of IDWG from equation 5.2, and the y-axis represents the 
observed IDWG. The solid 450 line represents the performance of the ideal predictive 
equation, with thick dashed 450 lines on either side to depict +/- 0.5 Liters. Most (15/24, 
62.5%) observations fell within 0.5 L of predicted IDWG, and almost all (22/24, 91.7%) 
fell within 1.0 L of predicted IDWG. The line of best fit of the grouped observations (thin 
dashed line) was almost superimposed upon the ideal predictive equation (solid line). The 
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correlation between predicted and observed IDWG (Figure 5.3) was strong (R2 = 0.51, 
95% CI 0.25 to 0.75, p<0.001). 
A Bland-Altman plot was completed (Figure 5.4). The x-axis represents the average of 
predicted (from Equation 5.2) and observed IDWG. The y-axis represents the observed 
minus the predicted IDWG. The correlation between difference and average IDWG 
(Figure 5.4) was strong (R2 = 0.49, 95% CI 0.18 to 0.74, p<0.001), suggesting that the 
difference between observed and predicted IDWG increases with increasing magnitude of 
IDWG.  
Figure 5.3: Calibration Plot for External Validation Cohort for Equation 5.2 
5.4 Discussion 
Increased IDWG is associated with hypertension,1,2,6,8 left ventricular hypertrophy and 
cardiovascular morbidity and mortality.3 IDWG is influenced by many factors, but salt 
balance is one of importance. Dietary salt restriction reduced IDWG, hypertension and 
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LVH in a Turkish hemodialysis population, while increased salt intake increased 
IDWG.21 
Table 5.5: Interdialytic Weight Gain in Patients for External Validation 
Factors associated with the dialysis treatment may also influence salt balance. The use of 
a dialysate with a Na+ greater than the pre-dialysis plasma Na+ will lead to diffusive Na+ 
gain by the patient and therefore the need to increase convective removal by 
ultrafiltration to restore Na+ balance. Keen and Gotch have shown that the difference 
between dialysate Na+ and pre-dialysis plasma Na+ positively correlates with IDWG.22 
Figure 5.4: Bland-Altman Plot of Observed Minus Predicted Interdialytic Weight Gain  
       Versus Average Interdialytic Weight gain 
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Several studies have shown that reducing dialysate Na+ concentration will reduce 
IDWG and improve outcomes.2-8 The dialysate to patient pre-dialysis Na+ difference is 
clearly an important factor in this area. Theoretically, the time and frequency of patient 
exposure to this difference should also influence Na+ balance and IDWG but, to date, this 
appears to have escaped attention. It may be of relevance that the patients undergoing 
nightly hemodialysis had significantly higher IDWG than those treated by short hours 
daily hemodialysis in the London Daily/Nocturnal Hemodialysis study when both were 
using a dialysate Na+ concentration of 140 mmol/L.10 Whether reductions in dialysate 
Na+ concentration are always desirable remains controversial; recent work suggests that 
reductions in IDWG need to be achieved in context of other potentially adverse 
outcomes.23 Prospective controlled trials are certainly indicated. 
The reduction of plasma Na+ over the course of dialysis also influences IDWG. 
We have previously shown that progressive reduction of the end dialysis plasma 
conductivity (Na+) using a biofeedback control system (DiaControl, Gambro Ab, 
Sweden) leads to increased ionic mass removal (Na+) by diffusion and significant 
reductions in IDWG, extracellular water and blood pressure.24 Whether the dialysate to 
pre-dialysis plasma Na+ difference, or the pre to post dialysis plasma Na+ change more 
strongly determines IDWG was uncertain although Hecking and colleagues recently 
showed that the latter was more predictive of clinical outcomes.8 The Na+ difference 
must be the driving force for the plasma Na+ change but other factors will influence that 
change such as the pre-dialysis plasma Na+ and the duration of the dialysis treatment. It 
is also possible the plasma albumin via the Gibbs-Donnan effect is of influence. 
From the clinical perspective, it is desirable to understand the factors that 
influence IDWG. There may be factors that can be modified within the dialysis 
prescription. It is accepted that this cannot be finite and that attention must also be given 
to psychosocial aspects of salt and water intake. Thus, as part of a Quality Initiative, the 
records of our home HD patients were examined creating an ideal study because 
treatment modalities included use of extended times and frequency. Furthermore, pre and 
post dialysis plasma Na+ levels had been routinely measured.  
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Knowing the availability of data we chose as possible independent variables that 
influence IDWG: age, sex, diabetic status, residual renal function, duration and frequency 
of dialysis treatments, and either DPNa+ or PPNa+. The results of univariable regression 
analysis showed that PPNa+ was more predictive than DPNa+, supporting the work of 
Hecking.8,12 Diabetic status and residual renal function did not appear to predict IDWG 
based on the univariable and multivariable models (Table 5.2).  The remaining 
independent variables were used in the multivariable analysis in Equation 5.1. This 
indicated significant associations between IDWG and dialysis frequency, PPNa+, plasma 
albumin, and age.  Female sex was included in this model despite not being statistically 
significant because it appeared to improve the model. 
A moderate correlation of PPNa+ with the product of dialysis duration and 
DPNa+ was found (Pearson coefficient = 0.4054).  Thus, a multivariable linear regression 
model was developed for Equation 5.2, which determines IDWG as a function of 
independent variables known before dialysis, eliminating the post-dialysis plasma Na+ 
value. These are the product of DPNa+ and dialysis duration, plasma albumin, female 
sex, and dialysis frequency. Patient age was also included in this model despite not being 
statistically significant, because it generally improved the predictive ability of the model. 
An internal bootstrap validation to investigate the predictive properties and model 
selection was conducted and showed reproducibility of our model selection, suggesting 
that the predictive model covariates in Equation 5.2 are stable for our data. External 
validation with a temporally distinct group of new patients showed excellent predictive 
ability of Equation 5.2. While Bland-Altman plot (Figure 5.4) shows that IDWG is 
underestimated at high IDWG, almost all (91.7%, 22/24) of observed and predicted 
IDWG are within 1.0 L, and most (62.5%, 15/25) are within 0.5 L (Figure 5.3). Equation 
5.2 does provide clinically important information. The use of a generic dialysate with 
Na+ content of 140 mmol/L is not desirable for patients undergoing nightly dialysis for 6 
to 8 hours per treatment when most (75/86, 87.2%) of the patients have pre-dialysis 
plasma Na+ levels lower (Figure 5.1). A positive Na+ difference of 5 mmol/L, found in 
16.3% (14/86) of our patients, will itself account for 0.42 Liters of IDWG (equation 5.2) 
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in these circumstances. In most patients, the difference should be zero or even slightly 
negative. As a result of this quality initiative study, our local practice will change.  
The study is limited by the relatively small number of patients studied and the 
retrospective review of laboratory and dialysis run sheet data (e.g. IDWG). Furthermore, 
all data points used are aggregates of variable numbers of dialysis and laboratory values 
obtainable at variable time periods corresponding to patients’ attendance at clinics. This 
may explain why equation 5.1 only provides 30% explanation for IDWG. Post-dialysis 
weight is not necessarily the dry weight; this likely influences dietary water and salt 
consumption, neither of which can be easily controlled for.. On the other hand, the study 
has strengths in that pre and post dialysis plasma Na+ values are available and the fact 
that a variety of dialysis modalities were used including short hours daily and long 
nightly. 
We have created an equation to predict IDWG on the basis of independent factors 
readily available before a dialysis session. The modifiable factors include dialysis time 
and frequency, and dialysate Na+. Patient sex, age and plasma albumin are also 
correlated to IDWG. Further work is required to establish how improvements in IDWG 
influence cardiovascular and other clinical outcomes. 
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6.1 Introduction 
Cardiovascular death is the leading cause of mortality in hemodialysis patients.1 A 
chronic state of volume and pressure overload is a major contributor2-5 leading to 
hypertension, left ventricular hypertrophy,6-10 and death.11,12 Considerable research has 
evaluated the effect of dialysis frequency and duration on clinical outcomes.6,13-15! It is 
well established that longer hemodialysis sessions improve outcomes13,14,16-19 including 
mortality.20-22 How this improvement relates to volume and pressure control remains 
controversial.  
In patients undergoing conventional thrice weekly hemodialysis, pre-dialysis 
plasma sodium is stable over time,23,24 and is thus called sodium setpoint (SP). When the 
dialysate sodium concentration exceeds the SP, diffusion of sodium into the patient 
occurs, and a number of undesirable clinical outcomes result, including increased 
interdialytic weight gain (IDWG), blood pressure, and ultrafiltration rate.25-30 These 
clinical outcomes are predicted by the magnitude not only of dialysate to pre-dialysis 
plasma sodium difference (DPNa+), but also by the post to pre-dialysis plasma sodium 
difference (PPNa+).30 However, there are no prospective trials evaluating personalized 
dialysate sodium in patients who dialyze more than thrice weekly, or longer than four 
hours per session. Quotidian and nocturnal hemodialysis patients are exposed more 
frequently and longer to a diffusion difference; how this alters clinical outcomes has not 
been prospectively evaluated. 
 Three objectives were tested in a randomized crossover study. The first objective 
was to determine how exposure to a higher DPNa+ altered IDWG, pre- and post-dialysis 
blood pressure, and ultrafiltration rate, in a study population that included conventional, 
quotidian and nocturnal hemodialysis patients. The second objective was to determine the 
effect of dialysis frequency and duration on each of the same clinical outcomes. The third 
objective was to establish which of PPNa+ or DPNa+ better predicted clinical outcomes. 
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6.2 Subjects and Methods 
Study Population 
All patients in the home hemodialysis program of the Southwestern Ontario Regional 
Renal Program were considered. Patients were excluded if they were under the age of 18, 
pregnant, or not expected to survive 6 months.  
Study Design 
A randomized crossover trial design was used (Figure 6.1). The average of the two most 
recent monthly pre-dialysis plasma sodium (Pre-Na+) measurements defined the patient’s 
sodium setpoint (SP). Patients were randomized to a dialysate sodium (Dial-Na+) 
concentration group either 3 mmol/L above (HIGHDialSOD period), or 3 mmol/L below 
(LOWDialSOD period) their SP (Figure 1). Dialysate sodium concentration range was 
restricted to between 130 and 150 mmol/L, because of concerns of clinical effects. After 
100 days, patients crossed over study periods. Patients were followed for another 100 day 
period, then the study was completed.  
Blood sample collection 
Pre-dialysis and post-dialysis blood samples were collected biweekly from the arterial 
blood line, using a standard slow blood and stop dialysate method. Locking solution (2 
mL of 4% citrate) and a small amount of blood (~2 to 5 mL) are spent prior to blood 
collection. The samples are centrifuged and refrigerated until delivered to the laboratory, 
within 12 hours of collection. Of interest in this study were pre-dialysis (Pre-Na+) and 
post-dialysis (Post-Na+) plasma Na+. Only outpatient blood tests were considered, to 
eliminate the confounding effect of acute illness. 
Na+ concentration measurement 
Plasma Na+ concentration was measured using Roche Modular P Chemistry Analyzer 
(Roche Diagnostics, Laval, Quebec, Canada) with ion selective electrodes. Dialysate Na+ 
concentration was determined using online conductivity measurements in the Fresenius H 
series hemodialysis machine.  
! 99!
 
Dial Na+ = dialysate Na+ concentration (mmol/L); SP = Pre-dialysis plasma sodium 
setpoint (mmol/L); LOWDialSOD = Time period when Dialysate sodium concentration = 
SP – 3 mmol/L; HIGHDialSOD = Time period when Dialysate sodium concentration = 
SP + 3 mmol/L 
 
Figure 6.1: Randomized Crossover Study Design 
 
Database creation 
Demographic, clinical and hemodialysis data were collected from the electronic patient 
record (Power Chart by Cerner), home hemodialysis run sheets and the outpatient 
hemodialysis unit paper chart. Background factors of interest included patient age, sex, 
diabetes status, height (cm), weight (kg), residual renal function (mL/min x 1.73 m2) and 
vintage of hemodialysis (days). Residual renal function was calculated as previously 
described.31 Hemodialysis records were used to record target weight (kg) and dialysis 
frequency (sessions per week) and duration (hours per session) throughout the study. 
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Outcomes collected included interdialytic weight gain (IDWG), pre- and post-
dialysis systolic and diastolic blood pressure, and ultrafiltration volume. IDWG was 
calculated as the difference between the post-dialysis patient weight and the next dialysis 
session’s pre-dialysis patient weight. Dialysate to pre-dialysis plasma sodium (DPNa+) 
and post- to pre-dialysis plasma sodium (PPNa+) concentration differences were 
recorded. We decided a priori that a minimum of 3 observations per study period would 
be required for each outcome, for a patient to be included in the final analysis.  
Ethics 
Ethics approval was granted by the Western University Health Sciences Research Ethics 
Board. Informed written consent was obtained from all patients. The study was conducted 
in accordance with the Declaration of Helsinki.  
Statistics 
Data were analyzed using the Statistical Package for Social Sciences version 19.0. The 
mean, median, standard error, and interquartile range were calculated for all background 
demographic and clinical factors.  
Statistics- Objective 1 
Each patient’s outcomes were averaged for each study period. Patients’ outcomes were 
then averaged for each study period, and compared using paired two-tailed student T-
tests, with an α value of 0.05 considered for statistical significance.  
Statistics- Objective 2 
Pearson correlation coefficients were calculated between each clinical outcome and 
firstly hemodialysis frequency, then hemodialysis duration. Each patient provided two 
data points in the analysis, one from each study period. Two-tailed p values with α of 
0.05 were used for statistical significance.  
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Statistics- Objective 3 
Pearson correlation coefficients were calculated between each clinical outcome and 
firstly DPNa+, then PPNa+. Two-tailed p values with α of 0.05 were used for statistical 
significance.  
DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = post- 
minus pre-dialysis plasma sodium concentration; HIGHDialSOD = when Dialysate 
sodium concentration Setpoint + 3 mmol/L; LOWDialSOD = when Dialysate sodium 
concentration = Setpoint – 3 mmol/L 
 
Table 6.1: Number of Observations per Clinical Outcome 
 
6.3 Results 
A total of 27 patients completed both study periods. All patients had at least 3 
observations for each outcome, and were thus included in data analysis. The mean and 
median observations were greater than 40 for all clinical outcomes in both 
HIGHDialSOD and LOWDialSOD study periods (Table 6.1). The mean and median 
observations were at least 3.0 for both DPNa+ and PPNa+ in both study periods.  
The study population’s background factors included an average age of 54.2 years, 
with 40.7% female and 33.3% diabetic (Table 6.2). Dialysis frequency averaged 4.4 
sessions per week, with a median of 4.0 weekly sessions. Dialysis duration averaged 4.8 
hours per session, with a median of 4.0 hours. More than half of study patients had no 
residual renal function, with a mean of 0.51 and median 0.00 mL/min.  
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Table 6.2: Background Demographic and Clinical Data 
 
Objective 1 
IDWG (2.15 vs. 1.90 kg, p=0.002), IDWG as % target weight (2.78 vs. 2.39%, p=0.002), 
pre-dialysis systolic (143.3 vs. 138.3 mm Hg, p=0.001), diastolic (78.6 vs. 75.6 mm Hg, 
p=0.008) and mean arterial pressure (100.2 vs. 96.5 mm Hg, p=0.003) and post-dialysis 
systolic (135.4 vs. 130.0, p=0.04), diastolic (75.8 vs. 72.4, p=0.006) and mean arterial 
pressure (95.7 vs. 91.6, p=0.009) were significantly higher in HIGHDialSOD than 
LOWDialSOD study period (Table 6.3). No change in target weight, or intradialytic 
change in systolic, diastolic or mean arterial pressure was found.  
Objective 2 
Hemodialysis frequency was inversely related to IDWG% (R = -0.295, Slope = -0.002, P 
= 0.034), and positively correlated with post-dialysis diastolic blood pressure (R = 0.366, 
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slope = 3.464, p=0.008)(Table 6.4). Hemodialysis duration was inversely correlated with 
ultrafiltration rate (R = -0.593, slope = -0.053, p<0.001) and positively correlated with 
IDWG (R = 0.562, slope = 0.184, p<0.001) IDWG% (R = 0.507, slope = 0.002, p<0.001) 
and intradialytic change in diastolic blood pressure (R = 0.280, slope = 1.127, p=0.044).  
HIGHDialSOD = when Dialysate sodium concentration Setpoint + 3 mmol/L; 
LOWDialSOD = when Dialysate sodium concentration = Setpoint – 3 mmol/L 
 
Table 6.3: Clinical Endpoints for Home Hemodialysis Patients in HIGHDialSOD  
      and LOWDialSOD Study Periods 
 
 
Objective 3 
Increased DPNa+ associated with increased IDWG (R = 0.346, slope = 0.001, p=0.012), 
pre-dialysis diastolic (R = 0 284, slope = 0.824, p= 0.041) and post-dialysis diastolic (R = 
0.325, slope = 1.084, p=0.019) and mean arterial (R = 0.292, slope = 1.030, p=0.036) 
blood pressure (Table 6.5). Increased PPNa+ associated with increased IDWG (R = 
0.306, slope = 0.001, p=0.029) and post-dialysis systolic (R = 0.181, slope = -0.067, 
p=0.049) blood pressure.  
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Bolded text denotes statistical significance 
 
Table 6.4: Pearson’s Correlation of the Clinical Outcome with Hemodialysis Frequency  
      and Duration 
 
6.4 Discussion 
In conventional thrice weekly hemodialysis, positive sodium balance is associated with 
IDWG, hypertension, left ventricular hypertrophy, and cardiovascular morbidity and 
mortality5,26-30,32,33 However, the clinical effects of frequent or prolonged exposure to 
higher dialysate sodium concentrations have not been prospectively evaluated. Our study 
population included patients on quotidian and nocturnal hemodialysis prescriptions 
(Table 6.2). There were a high proportion of females (40.7%) and diabetics (33.3%), and 
a wide spectrum of other demographic factors such as age and body habitus. 
Furthermore, each patient had multiple measurements of each clinical outcome in each 
study period. Thus, our study population was representative of a typical hemodialysis 
population, and the clinical outcomes were rigorously evaluated. 
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This study confirms that in a patient group with quotidian and nocturnal 
hemodialysis patients, personalization of Dial-Na+ higher than SP leads to several 
undesirable clinical outcomes, including IDWG, pre- and post-dialysis systolic, diastolic 
and mean arterial pressure (Table 6.3). This is consistent with previous trials in thrice 
weekly conventional hemodialysis patients.27-30 However, there was no difference in 
intradialytic change in systolic, diastolic or mean blood pressure between 
HIGHDialSOD. 
Bolded text denotes statistical significance; DPNa+= dialysate minus Pre-dialysis plasma 
sodium concentration; PPNa+ = post- minus pre-dialysis plasma sodium concentration 
 
Table 6.5: Pearson’s Correlation of Clinical Outcomes with  
      DPNa+ and PPNa+ Differences 
 
and LOWDialSOD study periods. Previous trials in thrice weekly conventional 
hemodialysis patients have demonstrated that low dialysate sodium increases risk for 
intradialytic hypotension.34-36 However intradialytic hypotension occurs when increases 
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in plasma volume from compartments outside plasma occur slower than hemodialysis 
reduces plasma volume.35,37 Our study population had longer hemodialysis duration than 
previous trials (mean 4.8 hours, interquartile range 3 -7 hours, Table 6.2). Since plasma 
refilling is dependent upon the ultrafiltration rate, longer hemodialysis likely tapered this 
effect and decreased the dependence of intradialytic blood pressure changes on dialysate 
sodium concentration.  
Whether and how dialysis frequency or duration modifies the clinical outcomes 
evaluated in this study is of clinical relevance. Our study confirms three important 
relationships. Firstly, hemodialysis frequency associates with decreased IDWG% (Table 
6.4). Consider the common clinical situation of a patient undergoing thrice weekly 
conventional hemodialysis with persistent volume overload and recurrent intradialytic 
hypotension. Increased dialysis frequency could improve fluid removal15,38,39 and a 
slightly positive DPNa+ difference would protect from intradialytic hypotension.34,36,40 
Our data provide evidence to support increasing hemodialysis frequency to decrease 
IDWG in such patients. Secondly, hemodialysis duration associates with an increased 
IDWG and IDWG%. While one might hypothesize that this relates to more prolonged 
exposure to a DPNa+ difference, the difference was positive in the HIGHDialSOD, but 
not in the LOWDialSOD study period. Therefore, this could reflect the common practice 
of avoiding food and drink during hemodialysis; this would disrupt dietary intake for 
conventional and quotidian, but not nocturnal patients. Thirdly, hemodialysis duration 
associated with increased intradialytic fall in diastolic blood pressure. Previous research 
has consistently shown that increased hemodialysis time decreases ultrafiltration rate and 
risk of intradialytic hypotension,22,27,34,41 contrary to this study’s findings. However, 
nocturnal hemodialysis patients often sleep during hemodialysis, so post-dialysis blood 
pressure is measured in the morning in a relaxed state, unlike the shorter hemodialysis 
sessions in conventional dialysis. Therefore, the intradialytic blood pressure change may 
relate also to vasomotor tone, rather than ultrafiltration rates.  
 DPNa+ was superior to PPNa+ in predicting IDWG%, pre-dialysis diastolic, post-
dialysis diastolic and mean arterial pressure (Table 6.5). These data are in contrast to a 
number of trials that suggest PPNa+ to be more predictive.30,42,43 Plasma Na+ approaches 
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Dial-Na+ throughout hemodialysis, so intradialytic change in plasma Na+ was predicted 
to be less than 3 mmol/L in our study, since Dial-Na+ was randomized to be 3 mmol/L 
above (HIGHDialSOD) or below (LOWDialSOD) the SP. Indeed, mean PPNa+ was 
quite low in our study (LOWDialSOD PPNa+ = -1.08 mmol/L; HIGHDialSOD PPNa+ = 
0.57 mmol/L), so PPNa+ was too small to overcome the lack of precision in the plasma 
Na+ measurement. However, use of the PPNa+ difference has the disadvantage of using 
Post-Na+ and therefore not being known prior to a hemodialysis session. Knowing that 
DPNa+ predicts clinical outcomes better than PPNa+ when Dial-Na+ is 3 mmol/L above 
or below the SP provides useful information, and helps guide selection of dialysate 
sodium to improve clinical outcomes. Furthermore, it makes measuring Post-Na+ 
unnecessary so long as Dial-Na+ is within 3 mmol/L of the Pre-Na+.  
This study does have limitations. Firstly, we did not record dialysis membrane 
surface area or blood glucose,44-47!each of which can impact diffusive sodium balance on 
hemodialysis. However, use of a randomized crossover design negated these effects, 
since each patient served as their own control, and since these factors were unlikely to 
change for any particular patient between study periods. Secondly, our study population 
was small. Despite this, an abundance of clinical endpoints and numerous pre- and post-
dialysis sodium values were available from all patients on multiple dialysis modalities. 
We were still able to report important outcomes of statistical and clinical significance.  
In conclusion, higher personalized dialysate sodium concentrations lead to 
increased interdialytic weight gain, pre- and post-dialysis blood pressure, and 
ultrafiltration rates in a patient population that includes conventional, quotidian and 
nocturnal hemodialysis patients. While hemodialysis frequency associates with decreased 
IDWG%, the opposite relationship is seen with hemodialysis duration. Furthermore, 
longer hemodialysis leads to greater falls in diastolic blood pressure, counter to previous 
research findings. DPNa+ difference is preferable to PPNa+ to predict clinical outcomes 
so long as the Dial-Na+ is personalized within 3 mmol/L of the SP. Further work is 
needed to establish the effect of personalizing the dialysate sodium concentrations on 
long-term cardiovascular outcomes in quotidian and nocturnal hemodialysis patients. 
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Chapter 7: Effect of Personalized Dialysate Sodium Prescription on Plasma Sodium 
Concentration and Sodium Setpoint in Conventional, Quotidian and Nocturnal 
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7.1 Introduction  
Cardiovascular disease is the leading cause of mortality in hemodialysis patients.1  
Chronic volume and pressure overload are major contributing factors, leading to 
hypertension, left ventricular hypertrophy and death.2-5 Several strategies to improve 
these risk factors have demonstrated success, including dietary sodium restriction,6,7 
increasing hemodialysis frequency and duration,8-13 and volume management guided by 
bioimpedance.14,15 Of recent relevant interest to this topic is the dialysate sodium 
prescription.16-18 
Pre-dialysis plasma sodium concentration is relatively stable in thrice weekly 
conventional hemodialysis patients, and is thus termed the “sodium setpoint” (SP).19-21 
When dialysate sodium concentration is less than SP, increased diffusive sodium removal 
occurs, leading to improvement in interdialytic weight gain, pre- and post-dialysis blood 
pressure,16,18,22-24 and perhaps also in cardiovascular outcomes and mortality.25,26 
However, marked reduction in dialysate sodium concentration gives rise to intradialytic 
symptoms including intradialytic hypotension.27,28  This may be mediated by intradialytic 
shifts in plasma sodium concentration.27  
While effects of personalized dialysate sodium prescription are well described in 
conventional thrice weekly hemodialysis patients, these outcomes have not been 
prospectively evaluated in quotidian or nocturnal hemodialysis patients. Whether plasma 
sodium concentration changes during more frequent or longer hemodialysis sessions is 
unknown, and whether such changes impact the sodium setpoint has not been 
prospectively evaluated. Three objectives were tested in a randomized crossover study, in 
conventional, quotidian and nocturnal home hemodialysis patients. Our first objective 
was to determine if personalized dialysate sodium prescription modified plasma sodium 
concentration from the start to the end of a hemodialysis session. Our second objective 
was to determine if a change in dialysate sodium concentration altered the pre-dialysis 
sodium setpoint. Our third objective was to determine if dialysis frequency or duration 
modulated changes in either plasma sodium throughout dialysis or sodium setpoint. 
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7.2 Materials and Methods 
Study Population 
All patients in the home hemodialysis program of the Southwestern Ontario Regional 
Renal Program were considered. Patients were excluded if they were under the age of 18, 
pregnant, or not expected to survive 6 months. 
Study Design 
A randomized crossover trial design was used. The average of the two most recent 
monthly pre-dialysis plasma sodium (Pre-Na+) measurements defined the patient’s 
sodium setpoint (SP). Patients were randomized to a dialysate sodium (Dial-Na+) 
concentration group either 3 mmol/L above (DialNa+ = SP + 3 = HIGHDialSOD), or 3 
mmol/L below (DialNa+ = SP – 3 = LOWDialSOD) their SP (Figure 7.1). Dialysate 
sodium concentration range was restricted to between 130 and 150 mmol/L, because of 
concerns of clinical effects. After 100 days, patients crossed over study periods. Patients 
were followed for another 100 day period, then the study was completed.  
Blood sample collection 
Pre-dialysis and post-dialysis blood samples were collected biweekly from the arterial 
blood line, using a standard slow blood and stop dialysate method. Locking solution (2 
mL of 4% citrate) and a small amount of blood (~2 to 5 mL) are spent prior to blood 
collection. The samples are centrifuged and refrigerated until delivered to the laboratory, 
within 12 hours of collection. Of interest in this study were pre-dialysis (Pre-Na+) and 
post-dialysis (Post-Na+) plasma Na+. Only outpatient blood tests were considered, to 
eliminate the confounding effect of acute illness. 
Na+ concentration measurement 
Plasma Na+ concentration was measured using Roche Modular P Chemistry Analyzer 
(Roche Diagnostics, Laval, Quebec, Canada) with ion selective electrodes. Dialysate Na+ 
concentration was determined using online conductivity measurements in the Fresenius H 
series hemodialysis machine.  
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SP = Plasma sodium setpoint (mmol/); DialNa+ = dialysate Na+ concentration (mmol/L); 
Blue arrow denotes mean 
 
Figure 7.1: Prospective Randomized Crossover Study Design 
 
Database creation 
Demographic, clinical and hemodialysis data were collected from the electronic patient 
record (Power Chart by Cerner), home hemodialysis run sheets and the outpatient 
hemodialysis unit paper chart. Background factors of interest included patient age, sex, 
diabetes status, height (cm), weight (kg), residual renal function (mL/min x 1.73 m2) and 
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vintage of hemodialysis (days). Residual renal function was calculated as previously 
described.29 Hemodialysis records were used to record dialysis frequency (sessions per 
week) and duration (hours per session) throughout the study. 
Dialysate to pre-dialysis plasma sodium difference (DPNa+) and post-dialysis 
(Post-Na+) to pre-dialysis (Pre-Na+) plasma sodium difference (PPNa+) concentration 
were also recorded. We decided a priori that a minimum of 3 observations per DPNa+ 
and PPNa+ would be required in each of HIGHDialSOD and LOWDialSOD study 
periods for a patient to be included in the final analysis.  
Ethics 
Ethics approval was granted by the Western University Health Sciences Research Ethics 
Board. Informed written consent was obtained from all patients. The study was conducted 
in accordance with the Declaration of Helsinki.  
Statistics 
Data were analyzed using the Statistical Package for Social Sciences version 19.0. The 
mean, median, standard error, and interquartile range were calculated for all background 
demographic and clinical factors.  
Statistics- Objective 1 
The average pre- and post-dialysis plasma sodium concentrations were calculated for 
each patient for each study period. The group average pre- and post-dialysis plasma 
sodium concentrations were then compared between HIGHDialSOD and LOWDialSOD, 
using paired two-tailed student t-tests with an α value of 0.05 considered for statistical 
significance. 
Statistics- Objective 2 
A change in SP was defined in two ways (Figure 7.2). Firstly, the average Pre-Na+ 
differed between HIGHDialSOD and LOWDialSOD study periods. Secondly, the slope 
of Pre-Na+ (M100) over time differed between study periods. Differences were detected 
! 117!
using paired two-tailed student t-tests with an α value of 0.05 considered for statistical 
significance. 
Figure 7.2: Endpoints to Determine Change in Pre-Dialysis Plasma Sodium Setpoint 
 
Statistics- Objective 3 
Pearson correlation coefficients were calculated to determine if changes in SP were 
modulated by hemodialysis frequency or duration. Y axis included either change in pre-
Na+ or slope of Pre-Na+ from HIGHDialSOD to LOWDialSOD study periods. X axis 
included hemodialysis frequency or duration. Slope of correlation was calculated and 
two-tailed p values were determined with an α value of 0.05 for statistical significance. 
7.3 Results 
A total of 27 patients completed both study periods. All patients had at least 3 
observations for each of DPNa+ and PPNa+, and were thus included in the final analysis.  
Mean and median SP was 138.1 and 138.5 mmol/L, with an interquartile range of 135.5 
to 141.0 mmol/L (Figure 7.1, Table 7.1). The study population was an average age of 
54.2 years, with 40.7% female and 33.3% diabetic (Table 7.1). Dialysis frequency 
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averaged 4.4 sessions per week, with a median of 4.0 weekly sessions. Dialysis duration 
averaged 4.8 hours per session, with a median of 4.0 hours. More than half of patients 
had no residual renal function, with a mean of 0.51 and median 0.00 mL/min.  
Table 7.1: Background Demographic and Clinical Data 
 
Objective 1 
Pre-Na+ and Post-Na+ did not differ in HIGHDialSOD study period (137.4 to 137.8 
mmol/L, p=0.45). However, plasma Na+ fell throughout dialysis (136.8 to 135.0 mmol/L, 
p=0.002) in LOWDialSOD study period (Figure 7.3).  
Objective 2 
Pre-Na+ sodium setpoint decreased from HIGHDialSOD to LOWDialSOD study period 
(137.4 to 136.8 mmol/L, p=0.03) (Table 7.2). The slope of Pre-Na+ (M100) also 
decreased from HIGHDialSOD to LOWDialSOD study periods (0.014 to -0.015 
mmol/L/day, p=0.009). 
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HIGHDialSOD= when Dialysate sodium concentration is 3 mmol/L greater than pre-
dialysis plasma sodium “setpoint”; LOWDialSOD=when Dialysate sodium concentration 
is 3 mmol/L lower than pre-dialysis plasma sodium “setpoint.” 
 
Figure 7.3: Pre and Post-Dialysis Plasma Sodium Concentration with High (Period 1)  
       or Low (Period 2) Personalized Dialysate Sodium 
 
Objective 3 
The change in Pre-Na+ across study periods was not correlated to hemodialysis 
frequency (R = 0.264, p=0.193) or duration (R = 0.032, p=0.877) (Table 7.3). Likewise, 
the change in slope of Pre-Na+ across study periods was not correlated to hemodialysis 
frequency (R = 0.172, p=0.401) or duration (R=0.067, p=0.745).  
7.4 Discussion 
Reduction in dialysate sodium concentration can reduce IDWG, blood pressure and 
negative cardiovascular outcomes.16,18,23 However, it may also give rise to intradialytic 
hypotension,27,28 mediated by intradialytic shifts in plasma sodium concentration.27 
Whether personalized dialysate sodium prescription associates with intradialytic shifts in 
plasma sodium in quotidian or nocturnal hemodialysis patients is previously unreported.  
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HIGHDialSOD = Dialysate sodium concentration 3 mmol/L higher than pre-dialysis 
sodium setpoint; LOWDialSOD = Dialysate sodium concentration 3 mmol/L lower than 
pre-dialysis sodium setpoint. Bolded text denotes statistically significant changes. 
 
Table 7.2: Difference in Absolute and Slope of Pre-Dialysis Plasma Sodium Setpoint  
      with Two Personalized Dialysate Sodium Concentrations 
 
P = p value; R = Pearson’s correlation coefficient 
 
Table 7.3: Effect of Hemodialysis Frequency and Duration on Change Across Study  
      Periods in Absolute and Slope of Pre-Dialysis Sodium Setpoint 
 
This randomized crossover study included patients with a spectrum of dialysis 
frequency (mean = 4.4, interquartile range = 3 to 6 sessions per week) and duration 
(mean = 4.8, interquartile range 3-7 hours)(Table 7.1). There was a high number of 
females (40.7%) and diabetics (33.3%) and a wide spectrum of other demographic and 
clinical factors such as blood pressure, age and body habitus. Every patient had at least 3 
recordings of PPNa+ and DPNa+ during each study period. The sodium setpoint (SP) 
varied widely in our study population (interquartile range 135.5 to 141.0, Table 1 and 
Figure 7.1). Thus, our study population was representative of a typical hemodialysis 
population, and outcomes were evaluated with rigor.  
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While the HIGHDialSOD plasma sodium did not change over dialysis (137.4 to 
137.8 mmol/L, p=0.45), there was a significant decrease from Pre-Na+ to Post-Na+ in the 
LOWDialSOD study period (136.8 to 135.0 mmol/L, p=0.002)(Figure 7.3). This is 
consistent with Suckling et al’s recent work.27 While the magnitude of intradialytic 
plasma sodium change was small in our study, there is still reason for concern. Firstly, 
intradialytic decrease in plasma sodium is linked to intradialytic hypotension,27 which 
independently increases risk of death.28 Secondly, ignoring patient-specific SP by facility 
level decreases in dialysate sodium concentrations will lead to significantly negative 
DPNa+ differences in some patients. Again, this increases the risk of intradialytic 
hypotension. Ultimately, selection of dialysate sodium should be personalized to the 
patient to limit adverse outcomes of a very positive DPNa+, while simultaneously 
avoiding the complications of intradialytic plasma sodium shifts from a negative DPNa+; 
this can only be done by regularly following the Pre-Na+ and adjusting the Dial-Na+ 
accordingly.  
 While Pre-N+ is stable as a “setpoint” in thrice weekly conventional hemodialysis 
patients,19-21 this has not been prospectively evaluated in quotidian or nocturnal 
hemodialysis patients. A retrospective study by our research group found that conversion 
from thrice weekly conventional to quotidian hemodialysis associated with a reduction in 
SP, when DPNa+ was neutral or negative.30 We confirm a change in SP prospectively in 
this study, as mean pre-Na+ (137.4 vs. 136.8 mmol/L, p=0.03) and slope of pre-Na+ 
(0.014 vs. -0.015 mmol/L/day, p=0.009)(Table 2) differ between HIGHDialSOD and 
LOWDialSOD study periods. While the magnitude of the change in pre-Na+ is small, 
this is both statistically and clinically important. Firstly, decreases in sodium setpoint are 
independently associated with increased mortality.31,32 Secondly, hemodialysis units that 
use facility wide dialysate sodium prescriptions will lead many patients to having highly 
negative DPNa+ and thus more exaggerated decreases in SP. Thirdly, in units that 
personalize dialysate sodium by following Pre-Na+, repeated decreases in Dial-Na+ to 
maintain a negative DPNa+ could cause repeated and undesirable decreases in SP. 
Finally, this raises the possibility that hemodialysis prescription might be modified to 
increase SP in vulnerable patients. More research will be required to determine the 
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pathophysiologic mechanism of a change in SP in these patients, and to determine the 
impact on cardiovascular outcomes. 
 There are limitations to this study. Firstly, we did not measure blood glucose, 
lipids or paraprotein levels, each of which can impact plasma sodium measurement.33-35 
However, use of a randomized crossover study design negated these effects, since each 
patient served as their own control, and since these factors were unlikely to change for 
any particular patient between study periods. Secondly, our study population was small. 
However, our patients are highly compliant, having participated in multiple previous 
research trials.12,13 This enabled the recording of numerous pre- and post-dialysis sodium 
values from all patients on multiple hemodialysis modalities. We were thus able to report 
statistically and clinically significant outcomes.  
 In conventional, quotidian and nocturnal hemodialysis patients, the 
personalization of Dial-Na+ to lower than the SP decreases plasma sodium throughout 
hemodialysis. Furthermore, Dial-Na+ can modify the Pre-Na+ “setpoint.” Further 
research is needed to determine the effect on cardiovascular morbidity and mortality. 
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8.0 General Discussion and Conclusions 
The most common cause of death in patients with end stage kidney disease is 
cardiovascular (Figure 1.1).1 A major contributor is the chronic state of volume and 
pressure overload,2-8 which leads to left ventricular hypertrophy9-17 and death.18,19 Of 
critical importance is the total sodium balance during a hemodialysis session,8,20-24 which 
is determined by the sum of diffusion and osmosis.  
 Diffusive balance during hemodialysis reflects the effects of several factors 
(Equation 1.4). Many factors are not modifiable, such as dialyzer hollow fiber radius 
(Chapter 1.1.1.1 and 1.1.1.2), length (Chapter 1.1.1.1 and 1.1.1.3) or thickness (Chapter 
1.1.1.4). Likewise, several factors must be maintained within a narrow range, such as 
dialysate temperature (Chapter 1.1.1), patient hematocrit and albumin (Chapter 1.1.1.8). 
On the other hand, the hemodialysis frequency and duration can be modified, as can the 
difference between dialysate and pre-hemodialysis plasma sodium concentrations 
(DPNa+). In Chapter 4, using retrospective data, we confirm that the post- to pre-dialysis 
plasma sodium difference (PPNa+) is superior to DPNa+ to predict clinical outcomes 
such as interdialytic weight gain, blood pressure, and the change in blood pressure during 
a hemodialysis session.25 However, the opposite was found using prospective data 
(Chapter 6). This could be because the magnitude of the DPNa+ and PPNa+ difference 
was much smaller as the study design involved personalization of the dialysate sodium 
within 3 mmol/L from the pre-hemodialysis plasma sodium concentration, or “setpoint.” 
This is an important observation for three reasons. Firstly, there is no clinical advantage 
to current practice of performing pre- and post-hemodialysis plasma sodium 
concentrations, so long as the dialysate sodium concentration is within 3 mmol/L of the 
setpoint. Secondly, the dialysate sodium concentration can be chosen before a dialysis 
session, making it modifiable, unlike the post-dialysis plasma sodium concentration. 
Finally, it confirms that the selection of dialysate sodium concentration greater than the 
setpoint leads to undesirable increases in interdialytic weight gain and blood pressure.  
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 Selection of dialysate sodium concentration within 3 mmol/L of the setpoint 
requires knowing it will remain stable over time. Previous trials confirm setpoint stability 
in thrice weekly conventional hemodialysis.26-28 However, the setpoint is not stable in a 
patient population of quotidian, conventional and nocturnal hemodialysis patients, 
retrospectively in Chapter 3,29 nor prospectively in Chapter 7. Use of a Dial-Na+ of 140 
mmol/L led to decrease in setpoint in patients with pre-hemodialysis plasma sodium 
concentration greater than or equal to 140 mmol/L (Chapter 3). Furthermore, 
personalization of dialysate sodium concentration 3mmol/L less than the SP leads to a 
decrease in setpoint (Chapter 7). Given that low pre-hemodialysis plasma sodium 
concentration independently predicts mortality,30 this is an important observation. This 
gives pause to the practice of increasing diffusive sodium loss by using a dialysate 
sodium concentration lower than the pre-hemodialysis plasma sodium concentration. 
Further research is required to determine if intentional increases in setpoint are possible 
or beneficial for cardiovascular and all-cause morbidity and mortality.  
 The factors that determine interdialytic weight gain are important to delineate, so 
that they may be modified prior to a hemodialysis session. In Chapter 5, those variables 
were determined to be dialysis time, frequency and dialysate sodium.31 Furthermore, 
several unmodifiable factors were important, including patient sex, age and serum 
albumin. Ultimately, an equation was created that was validated internally using 
bootstrapping and externally using a temporally distinct patient subset. Our research 
group is currently prospectively validating this equation, with a dataset that includes 
patients with a variety of dialysate sodium concentrations, dialysis durations and 
frequencies, and residual renal functions.  We hope to finish this work by June, 2015. 
 As plasma water is removed from a patient, plasma hematocrit increases during 
hemodialysis, causing an increase in blood viscosity (Section 1.1.1.8). As interdialytic 
weight gain increases, the requirement for fluid removal during hemodialysis also 
increases, and thus also blood viscosity. Since increases in blood viscosity lead to 
decreased diffusive sodium loss (Equation 1.5), one might hypothesize that the increased 
mortality from higher interdialytic weight gain occurs partially due to decreased solute 
clearance towards the end of hemodialysis, when blood viscosity reaches its maximum. 
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As our equation is validated in more populations, we will need to establish the effect of 
blood viscosity on solute clearance and mortality. This hypothesis evidently needs further 
evaluation.  
 While hemodialysis equipment modification was not the focus of this thesis, it is 
noteworthy that the design of materials already considers Poiseuille’s Law (Equation 
1.7). Specifically, it is desirable not to have increased pressure drop across the hollow 
fiber of the dialysis membrane; this prevents backfiltration of the dialysate, which is 
undesirable (Section 1.1.1.2 and 1.1.1.3). Even a small (10%) increase in hollow fiber 
radius causes a large (46%) decrease in blood flow resistance. So long as the blood flow 
is constant, this leads to a significant increase in the pressure drop over a hollow fiber, 
which again leads to backfiltration of dialysate  (Equation 1.8). Similarly, a long hollow 
fiber would increase pressure drop (Equation 1.7), but would also increase surface area 
for diffusion (Equation 1.6). It is thus inevitable that advances in hemodialysis 
technology will play a key role in optimizing safe diffusive and osmotic sodium removal  
in the years to come. In light of these future trials designed to improve hemodialysis 
technology, our work will play a key role in assuring their safe and effective design. 
Specifically, it will be essential to monitor the pre-dialysis plasma sodium setpoint to 
assure stability. Use of the DPNa+ and PPNa+ concentration differences under particular 
circumstances that have been defined by our studies will also be important. Finally, 
focusing on factors that are modifiable for patients’ interdialytic weight gain will improve 
the yield of such studies.  
Hemodialysis prescription continues to be an essential consideration in improving 
cardiovascular mortality in patients with end stage kidney disease. Future research will 
need to combine dialysis prescription with monitoring measurements such as 
bioimpedance. While low dialysate sodium improves clinical outcomes such as 
interdialytic weight gain and blood pressure, it is associated with decrease in setpoint in 
patients on frequent or longer hemodialysis treatments. It is thus proposed that sodium 
balance-neutral or slightly positive is a preferable choice, ensuring quality dialysis with 
minimal sodium gain-related complications. Only with careful monitoring of pre-dialysis 
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setpoint and personalized selection of dialysis frequency, duration and dialysate sodium 
concentration can outcomes be optimized.  
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